CN116710177A - Apparatus and method for applying photo-biological conditioning - Google Patents
Apparatus and method for applying photo-biological conditioning Download PDFInfo
- Publication number
- CN116710177A CN116710177A CN202180080898.6A CN202180080898A CN116710177A CN 116710177 A CN116710177 A CN 116710177A CN 202180080898 A CN202180080898 A CN 202180080898A CN 116710177 A CN116710177 A CN 116710177A
- Authority
- CN
- China
- Prior art keywords
- pbm
- light
- adjust
- processing
- metabolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 127
- 230000000258 photobiological effect Effects 0.000 title claims abstract description 4
- 230000003750 conditioning effect Effects 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 104
- 230000002503 metabolic effect Effects 0.000 claims abstract description 90
- 230000003287 optical effect Effects 0.000 claims abstract description 85
- 238000012544 monitoring process Methods 0.000 claims abstract description 49
- 238000012545 processing Methods 0.000 claims abstract description 32
- 230000002123 temporal effect Effects 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 71
- 239000008280 blood Substances 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 55
- 206010021143 Hypoxia Diseases 0.000 claims description 42
- 230000000747 cardiac effect Effects 0.000 claims description 34
- 230000007954 hypoxia Effects 0.000 claims description 28
- 238000005259 measurement Methods 0.000 claims description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 208000010125 myocardial infarction Diseases 0.000 claims description 15
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 10
- 210000001147 pulmonary artery Anatomy 0.000 claims description 9
- 208000028867 ischemia Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000004980 dosimetry Methods 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 2
- 241000976983 Anoxia Species 0.000 claims description 2
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 2
- 230000007953 anoxia Effects 0.000 claims description 2
- 239000013060 biological fluid Substances 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 abstract description 23
- 230000004060 metabolic process Effects 0.000 abstract description 22
- 210000001519 tissue Anatomy 0.000 description 92
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 68
- 210000002216 heart Anatomy 0.000 description 36
- 238000005286 illumination Methods 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 34
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 229950003776 protoporphyrin Drugs 0.000 description 20
- 239000003642 reactive oxygen metabolite Substances 0.000 description 19
- 210000000056 organ Anatomy 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 239000001301 oxygen Substances 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 230000010410 reperfusion Effects 0.000 description 17
- 230000009885 systemic effect Effects 0.000 description 15
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 208000010496 Heart Arrest Diseases 0.000 description 13
- 238000009792 diffusion process Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 210000004165 myocardium Anatomy 0.000 description 11
- 229910052717 sulfur Inorganic materials 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 206010063837 Reperfusion injury Diseases 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 230000010355 oscillation Effects 0.000 description 9
- 230000006442 vascular tone Effects 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 229940016409 methylsulfonylmethane Drugs 0.000 description 8
- 230000001114 myogenic effect Effects 0.000 description 8
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 description 8
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 230000001146 hypoxic effect Effects 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000008092 positive effect Effects 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 238000002604 ultrasonography Methods 0.000 description 7
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000003837 chick embryo Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000002594 fluoroscopy Methods 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 210000005245 right atrium Anatomy 0.000 description 6
- 239000011669 selenium Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 102100025399 Breast cancer type 2 susceptibility protein Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102000004722 NADPH Oxidases Human genes 0.000 description 5
- 108010002998 NADPH Oxidases Proteins 0.000 description 5
- 238000004497 NIR spectroscopy Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229960002749 aminolevulinic acid Drugs 0.000 description 5
- 210000002565 arteriole Anatomy 0.000 description 5
- 238000010009 beating Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000001736 capillary Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- -1 hydroxyl radicals Chemical class 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 239000013307 optical fiber Substances 0.000 description 5
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 238000006303 photolysis reaction Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000007845 reactive nitrogen species Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000001360 synchronised effect Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000002902 bimodal effect Effects 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 239000005515 coenzyme Substances 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 210000002837 heart atrium Anatomy 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 229960002418 ivermectin Drugs 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000006540 mitochondrial respiration Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000010363 phase shift Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 230000001457 vasomotor Effects 0.000 description 4
- 210000001631 vena cava inferior Anatomy 0.000 description 4
- 210000002620 vena cava superior Anatomy 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 102000018832 Cytochromes Human genes 0.000 description 3
- 238000004435 EPR spectroscopy Methods 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 108010063312 Metalloproteins Proteins 0.000 description 3
- 102000010750 Metalloproteins Human genes 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 208000006218 bradycardia Diseases 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 108010002255 deoxyhemoglobin Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002565 electrocardiography Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000018875 hypoxemia Diseases 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001902 propagating effect Effects 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010058178 Aortic occlusion Diseases 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 2
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 2
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 2
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- HRLIOXLXPOHXTA-NSHDSACASA-N dexmedetomidine Chemical compound C1([C@@H](C)C=2C(=C(C)C=CC=2)C)=CN=C[N]1 HRLIOXLXPOHXTA-NSHDSACASA-N 0.000 description 2
- 229960004253 dexmedetomidine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000027721 electron transport chain Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 2
- 229960004657 indocyanine green Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002697 interventional radiology Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002840 nitric oxide donor Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 231100000760 phototoxic Toxicity 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 210000002321 radial artery Anatomy 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910000058 selane Inorganic materials 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241000169677 Acharia <angiosperm> Species 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 239000005746 Carboxin Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000021479 Cardiovascular injury Diseases 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010021034 Hypometabolism Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000298990 Kalinia Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108090000913 Nitrate Reductases Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 1
- 108010025915 Nitrite Reductases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000573490 Pseudoides Species 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108010074686 Selenoproteins Proteins 0.000 description 1
- 102000008114 Selenoproteins Human genes 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000006536 aerobic glycolysis Effects 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000009610 ballistocardiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006409 bimodal response Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- GYSSRZJIHXQEHQ-UHFFFAOYSA-N carboxin Chemical compound S1CCOC(C)=C1C(=O)NC1=CC=CC=C1 GYSSRZJIHXQEHQ-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000008209 cardiovascular development Effects 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000013153 catheter ablation Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000007960 cellular response to stress Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 150000001787 chalcogens Chemical group 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- LIXKIXWSKOENAB-UHFFFAOYSA-N cimlanod Chemical compound CC1=CC=C(S(=O)(=O)NO)O1 LIXKIXWSKOENAB-UHFFFAOYSA-N 0.000 description 1
- 229940121423 cimlanod Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011066 ex-situ storage Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 230000000745 ion overload Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 108010023015 ischemia-modified albumin Proteins 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 238000001748 luminescence spectrum Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 108010042248 nitrosyl hemoglobin Proteins 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 238000013146 percutaneous coronary intervention Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- VITHNLWMYSJJEU-UHFFFAOYSA-N reglin Natural products CC(C)C1=C(O)C(=O)C2=C(C(CC3C4(C)CCCC23COC4=O)OC(=O)C56CCC(C)(C)CC5C7=CCC8C9(C)CCC(O)C(C)(C)C9CCC8(C)C7(C)CC6)C1=O VITHNLWMYSJJEU-UHFFFAOYSA-N 0.000 description 1
- 231100001028 renal lesion Toxicity 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 description 1
- 229940032712 succinylcholine Drugs 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Landscapes
- Radiation-Therapy Devices (AREA)
Abstract
The present invention relates to an apparatus for applying photo-biological modulation (PBM) to a biological object, the apparatus comprising a light source delivering light at an appropriate temporal evolution of its optical power, the apparatus further comprising a processing and/or light control unit determining the appropriate temporal evolution of the optical power based on the light delivery geometry on/in the biological object and the biological object optical coefficients, characterized in that in each part of the volume of the biological object the PBM effect is caused continuously by generating one or more specific fluence rates during one or more specific times; in the following parametersThe fluence rate and the time of the specific combination are selected from the group: at 180+Period 3 of 30s+2mW/cm 2 Or at 80+25s period 11+9mW/cm 2 Or at 40+20s period 16+10mW/cm 2 Or at 15+Period of 10s 25+10mW/cm 2 Or at 40+Period 10 of 1s+9,7mW/cm 2 . The invention also relates to different methods for application to a biological object (PBM), comprising the light source delivering light at a suitable temporal evolution of its optical power as described above. The present invention also relates to the above-described devices and methods for using PBM, optionally in combination with exogenous agents that participate in or regulate metabolism. The present invention also relates to the above-described devices and methods for applying PBM, optionally in combination with probes for monitoring metabolic activity occurring in a biological subject. Such monitoring can define optimal PBM light application conditions according to the following aspects: i) Time relative to metabolic activity, ii) fluence rate, and iii) duration of irradiation.
Description
Corresponding application
The present application claims priority from international application PCT/EP2021059842 filed on 1 month 10 in 2020, and filed on 15 months 4 in 2021, the contents of which are incorporated herein by reference in their entirety.
Technical Field
The present application relates generally to photo bio-modulation (PBM) and more particularly to an apparatus and method for applying photo bio-modulation therapy (PBMT).
Background
Definition of the definition
The following definitions apply herein.
-light: electromagnetic radiation having a wavelength in the range of 250nm to 3 μm.
Irradiance or principal incidence (primary incidence) E [ W/m ] 2 ]: irradiance describes the power per unit surface received directly from a source.
Emissivity LW/(m) 2 .sr)]: emissivity is the power of light emitted through or from a unit surface area and propagating within a unit solid angle in a given direction.
Fluence rate FW/m 2 ]: fluence rate is the power into a sphere exhibiting a unit cross section. Which takes into account diffusion and/or scattering effects in the target environment. Fluence rates were measured with an isotropic power meter. Which takes into account the direct flux (irradiance) and the scattering and diffusion contributions. As with fluence (see below), this term is of fundamental importance in dosimetry where multiple scattering and diffusion in the target tissue are important.
Fluence or light dose ψ [ J/m ] 2 ]: is the time integral of the fluence rate. Thus, fluence is the energy that enters a sphere exhibiting a unit cross section.
Absorption coefficient mu a [m -1 ]: reciprocal of mean free path prior to photon absorption
Scattering coefficient mu s [m -1 ]: reciprocal of mean free path between photon scattering
Reduced scattering coefficient mu s '[m -1 ]:μ s '=μs(1-g)
-anisotropy factor g-: g is equal to the average of cos "theta", where "theta" is the deflection angle of the photons scattered by the particle.
Effective attenuation coefficient mu eff [m -1 ]:μ eff =(3μ a (μ a +μ s ')) 1/2
Photo-bioregulation, referred to herein as PBM, refers to the treatment of a biological object (e.g., a tissue or organ) with light of a specific wavelength. Such treatment may promote regeneration and remodeling of tissues or nerves, eliminate inflammation, alleviate edema, relieve pain, regulate the immune system and metabolism. It has a positive effect on age-related macular degeneration, blood treatment, wound healing, immunomodulation and possibly even on viral and bacterial infections.
Many conditions are associated with disturbances of metabolism, including defects in mitochondrial respiration. These conditions include chronic or acute inflammation such as neurodegenerative diseases (parkinson's disease, alzheimer's disease and huntington's disease), atherosclerosis, certain forms of diabetes, autoimmune diseases, cancer, chronic wounds, damage caused by ischemia reperfusion, and Acute Respiratory Distress Syndrome (ARDS). It is well known that in the case of stroke, heart attack, grafts or ischemic wounds, etc., the metabolism can change significantly. As an example, mitochondrial respiration has been shown to play an important role in cardiac remodeling [ Kindo,2016], and cardiac metabolism responds to wall pressure via mitochondrial dysfunction [ Kindo,2012].
Therefore, strategies to normalize, restore and/or increase metabolism are of great interest for the treatment and characterization of many conditions. PBM therapy is one of these strategies [ hamlin 2017; hammblin 2018].
PBM therapy is based on light application at low (sub-thermal) irradiance, with a primary wavelength range between 600 and 900nm, and a spectral window corresponding to the maximum light penetration depth in most soft tissues. PBM has a broad range of molecular, cellular and tissue effects [ hamlin 2017; hammblin 2018].
However, the mechanism is not fully understood. In addition, PBM treatment parameters are rarely optimized and/or mastered. Studies based on several groups [ hamlin 2017; hamlin 2018], and most importantly, from in vitro and in vivo observations made by the inventors, it can be concluded that PBM produces several positive effects, in particular:
a) Tissue oxygen (O) after or during hypoxia 2 ) The consumption is increased and the cost is increased,
b) The blood vessel formation is stimulated and the blood vessel,
c) The regeneration process is stimulated at the cellular level,
d) Increased endogenous production of protoporphyrin IX (PpIX) following application of 5-aminolevulinic acid (ALA) [ Sachar,2016 ]]Which can be used as O 2 A sensor. It should be noted that several ALA formulations for eliciting PpIX are approved for cancer therapy and detection as photosensitizers and fluorescent markers, respectively.
e) An increase in ATP production, indicative of an improved metabolic activity,
f) Regulation of Reactive Oxygen Species (ROS).
g) Regulation of Reactive Nitrogen Species (RNS).
h) Rescue of toxic cells.
i) Embryo survival, affected by hypoxia/reoxygenation events, increases.
j) An increase in circulating Nitric Oxide (NO) during prolonged hypoxic or hypoxic events.
k) Continuous steady state during prolonged hypoxia or hypoxic blood events (based on hemodynamic variables, blood gas measurements as blood glucose).
These observations may originate from the stimulation of metabolic activity and are of great interest for numerous medical applications including those described above [ hamlin 2017; hammblin 2018].
PBM is of particular interest in the treatment of Myocardial Infarction (MI) [ Liebert,2017], which is one of the most common acute disorders. It is a major cause of death worldwide. Currently, the treatment options chosen for patients with MI to limit their size and reduce acute myocardial ischemia injury are time consuming, have side effects and have limited efficacy. They include direct percutaneous coronary intervention or thrombolytic therapy. Furthermore, the treatment itself (reperfusion process), which is also known as myocardial reperfusion injury, may be responsible for myocardial cell death until several days after treatment for which there has been no effective treatment until now [ choucani, 2016; ferrari,2017; kalogeris,2017].
PBMT is also of interest in the treatment of systemic inflammation when the situation is for fibromyalgia, arthritis associated with rheumatism or autoimmune diseases, especially when circulating blood is directly irradiated. PBMT may also help avoid the consequences of SARS-Cov2 during the acute phase, where strong immune responses generated by cell division storms may induce Acute Respiratory Distress Syndrome (ARDS), or during the chronic phase resulting from long-term SARS-Cov2 effects.
US2007/219604A1 discloses a method of applying PBM on a biological object, wherein light is delivered with a suitable temporal evolution of the optical power, which is determined based on the light delivery geometry on/in the biological object and the biological object optical coefficient. In this patent application US2007/219604A1, the PBM effect is caused by the generation of fluence rates in each part of the biological object volume in turn. It is noted that the application does not mention specific values of fluence rate and irradiation time.
However, existing methods for applying PBM are not efficient enough, in particular because of the bimodal effect of PBM, as described below.
The limited use of PBMT can also be explained by the lack of methods to monitor metabolic activity of biological tissues. This statement is supported by another finding by the inventors, which suggests that the importance of the PBM effect depends on the time at which the metabolically active light is applied relative to, for example, that determined by oxygen consumption.
There is therefore a need for improved use of PBM for treatment of biological subjects.
Drawings
Fig. 1: the fluence rate/irradiance pair for "broad", collimated and perpendicular illumination of air tissue interfaces versus semi-infinite tissue depth. The continuous curve is a solution of diffusion approximation, while the dashed curve is a solution based on Monte Carlo computer simulation, where μ a Sum mu s The absorption and scattering coefficients, respectively. Mu (mu) eff Is the effective attenuation coefficient, g is the anisotropy factor, and k is the exponential front factor resulting from the back-scattering of light. Derived from [ Jacques,2010]。
Fig. 2: pO measured on single-layered HCM cells oscillated via metabolism 2 (black curve; mmHg) and temperature (gray curve; DEG C).
Fig. 3: synergistic effect of STS and PBM on angiogenesis.
Fig. 4a, 4b: various PBM conditions, expressed as PBM/PBM-free PpIX fluorescence intensity ratio, which reflect in particular metabolic activity, were observed in Human Cardiomyocytes (HCM) at 689nm (fig. 4 a) and 652nm (fig. 4 b). The value of the ratio "PBM/no PBM" is given by the monochrome bar.
Fig. 4c: left: fluence rate dependent effects at 689nm (effective wavelength (potent wavelength)) and 730nm (ineffective wavelength (non-potent wavelength)) range from 0.5 to 15mW/cm 2 ). Right: using an ineffective fluence rate (9 mW/cm 2 ) A combination of an effective wavelength with an ineffective wavelength that has a significant effect on the relative increase in PpIX fluorescence.
Fig. 5: evolution of fluence rate/irradiance ratio (F/E) for "broad", collimated and perpendicular illumination of air tissue interfaces to semi-infinite tissue depth. The continuous curve is a solution of diffusion approximation, while the dashed curve is a solution based on Monte Carlo computer simulation, where μ a Sum mu s The absorption coefficient and the scattering coefficient, respectively. Mu (mu) eff Is the effective attenuation coefficient, g is the anisotropy factor, and k depends on the index matching condition (n tissue /n air =1.37) and the optical coefficient, is the exponential front factor resulting from light back scattering. Derived from [ Jacques,2010]。
Fig. 6: pO in CAM at EDD 7 2 Is a frequency analysis of (a). Upper left: experimental images of a metallic clark probe applied against a blood vessel are shown. Left middle: pO (pO) 2 Signals (acquired at 50 Hz). Left lower: the associated spectrum based on wavelet analysis (vertical scale is frequency and monochromatic level represents oscillation amplitude, horizontal scale is time in s). The right lower: pO (pO) 2 Signals (acquired at 1 Hz) and top right: the monochrome level represents the oscillation amplitude of the associated spectrum produced by wavelet analysis. The horizontal axis is time given in minutes. pO was observed 25 minutes (out of scale time) after topical application of NaHS (10. Mu.l-1. Mu.M) 2 Intense activation of tone, naHS, which was initiated by PBM (850 nm,7 mW.cm) 2 30 s) is deactivated (see myogenic signal). The horizontal line reported on the spectrum indicates a particular frequency. 1-heart, 2-breath, 3-myogenic, 4-neurogenic, 5-eNOS dept,6-eNOS index (possibly prostaglandin [ Shiogai et al)]). Heart frequency cannot be in samplingSolving the problem. There are no respiratory and nerve bands at this EDD.
Fig. 7: an enlarged view of the experiment is presented in fig. 6. The horizontal axis gives the time in minutes.
Fig. 8: left: images of in ovo hypoxia reoxygenation experiments. Right: pO recorded throughout the experiment 2 Signal (OX-100 μm)) (vertical axis: mmHg). Due to N 2 Flushing (up to 60 minutes) results in hypoxia followed by reoxygenation.
Fig. 9: stimulation of the chick embryo heart at EDD 5 by PBM during hypoxia cardiac arrest. Left: time course measurement of heart beat (assessed by changes in heart reflectivity in a region of interest defined by a rectangle presented on the image showing the embryo (right)). The heartbeat stops between 0 and 45 s. The heartbeat was then reactivated by PBM irradiation during 7s for more than 1min.
Fig. 10: spatial evolution of fluence rate (E) in semi-infinite tissue for "broad", collimated and perpendicular illumination of air tissue interfaces. Δz=0.3 mm; n=10; n is n tissue/ n air =1.37;
T=180s;ΔF’=1.6mW/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the The dashed curve corresponds to a continuous fit of the fluence rate "step-wise" evolution. The fitted analytical expression is presented as an inset in the graph. This means that E may be continuously changing rather than incrementally changing.
Fig. 11: time evolution of fluence rate (E) in semi-infinite tissue for "broad", collimated and perpendicular illumination of air tissue interfaces. Δz=0.3 mm; n=10; n is n tissue /n air =1.37;T=180s;ΔF’=1.6mW/cm 2 The method comprises the steps of carrying out a first treatment on the surface of the The dashed curve corresponds to a continuous fit of the fluence rate "step-wise" evolution. The fitted analytical expression is presented as an inset in the graph. This means that E may be continuously changing rather than incrementally changing.
Fig. 12: overview of a 90 ° transapical implantation during coronary thrombosis (b) of a cylindrical dispenser (d) connected to a light source (a), the cylindrical dispenser passing through a maskPlaced across the myocardium in a predefined pattern and spacing. (e) An optical distributor,A catheter and a guide device to be inserted into the catheter for penetration. (f) The image shows the light transmission (652 nm-100 mW) from an isotropic distributor (sphere 0.8mm diameter) implanted in the center of the left ventricular myocardium of an ex vivo pig.
Fig. 13: in situ implantation following sternotomy, along the damaged left ventricle of the pig heartA catheter. A) The catheter is introduced from the apex side until it comes out B) from the top of the left ventricle). C) The heart cross section of the catheter was not removed after cardiac ablation. Where the catheter is placed well near the middle of the myocardial thickness.
Fig. 14a: visual localization of ischemic area (IZ) following left anterior coronary descending (LAD) occlusion of a partially perfused left ventricle during open heart surgery in pigs. IZ is easily distinguished from non-ischemic zones (NZ). Electrical impedance sensors may also be used to characterize ischemic areas.
AJP cardiac cycle physiology
Fig. 14b: after LAD occlusion during open heart surgery on pigs, a visual representation of the transapical light modulation described in example 1. During ischemia, the interstitial catheter is used for treating the ischemiaThe left myocardium is inserted from the apex to the left atrium, with the distance between them being optimal to maximize the treatment area. Then the cylindrical dispenser (+)>Rod length 7 cm) is placed at each +.>Is a kind of medium. PBM treatment is initiated for a few seconds to a few minutes depending on the irradiation time prior to reperfusion. Several seconds prior to ventricular reperfusion, used to670nm and 808nm from both dispensers. The catheter is then removed immediately after reperfusion. Finally, they can be placed in position after surgery for further regenerative irradiation.
Fig. 15: a simplified diagram shows a portion of an example of an apparatus for providing therapy. Depending on the disease and the method of treatment, e.g. interstitial or systemic, the device may be modular with a combination of different basic communication blocks. Some of the blocks may be based on observable sensors as described in this document, or interfaces to acquire data from common clinical systems. Some blocks may characterize the spectrum of illumination, while other blocks may be dedicated to controlling the exogenous perfusion and perfusion temperature into the catheter. Other actuators may also be added to the combined exogenous stimuli, such as a function of mechanical pressure or temperature of the PBM. In the case of a multi-lumen balloon catheter, as shown herein, some blocks may control the time and/or period and/or level of inflation/deflation, with or without regard to monitoring of changes. A portion of the device also integrates a specific balloon size and shape to optimally treat biological objects. For example, as shown, the balloon at the center of the right atrium assumes two opposite conical shapes, which optimally treat circulating objects from the superior and inferior vena cava. Furthermore, since PBM strongly affects biological rhythms, especially during hypoxia or hypoxemia, the balloon can be shaped to contact the sinoatrial node at the top of the right atrium or to contact the atrial-ventricular node. In addition, using a multilumen catheter, exogenous agents may be injected through the balloon either upstream or downstream of the irradiation function of the agent. Obviously, the device can also be used for photoactivation of photosensitizers. The blocks of these devices can also be implemented directly by various implants to minimize platelet aggregation and clotting on the heart valve. It may also be implemented, for example, on artificial heart or pancreatic chambers to increase biocompatibility/biostability, and/or may be implemented to reduce inflammation and immune response of implanted chambers used in chemotherapy, and as other examples, activate endothelialization of hip prostheses or vascular stents.
Fig. 16: examples of irradiance geometries used in PBM. Stippled areas schematically represent patterns of fluence rates in tissue. (a) (b) surface irradiation from a broad beam or lens head fiber. (c) - (e) irradiating with the cut ends or interstices of the cylindrical fibers. (f) - (h) intracavity and intracavity irradiation. (i) (j) intracavity full surface irradiation with isotropic tip fibres or light diffusing liquid (shadows).
The source is as follows: wilson,1986.
Fig. 17: spatial evolution of fluence rate (E) in semi-infinite tissue for "broad", collimated and perpendicular illumination of air tissue interfaces. The spatial evolution of E is optimized so that its value never exceeds 100mW/cm 2 While minimizing the total irradiation time. The idea is to illuminate the sample with two PBM hot spots visible in fig. 4, i.e. generating 15 and 3mW/cm during 40 and 180s (T-value), respectively 2 Is a function of the integrated flux rate of (a). The corresponding values of Δf', Δz and n (steps) are respectively:
-4mW/cm 2 0.15mm and 13 for t=40s
-1.6mW/cm 2 0.3mm and 4 last t=180 s.
n tissue /n air =1.37。
Fig. 18: time evolution of fluence rate (E) in semi-infinite tissue for "broad", collimated and perpendicular illumination of air tissue interfaces. The spatial evolution of E is optimized so that its value never exceeds 100mW/cm 2 While minimizing the total irradiation time. The idea is to illuminate the sample with two PBM hot spots visible in fig. 4, i.e. generating 15 and 3mW/cm during 40 and 180s (T-value), respectively 2 Is a function of the integrated flux rate of (a). The corresponding values of Δf', Δz and n (steps) are respectively:
-4mW/cm 2 0.15mm and 13 for t=40s
-1.6mW/cm 2 0.3mm and 4 last t=180 s.
n tissue /n air =1.37。
The "step-based" evolution of fluence rate can be fitted by an analytical expression presented as an inset in fig. 11.
Fig. 19a: illustrating non-uniformity along with non-uniform longitudinal emissivity from a cylindrical dispenserLight emissivity. The dispenser (2) is placed in a container delimited by a wall container (1). The emissivity of the dispenser is shaped to produce a light gradient along the rod (the light emitting portion of the dispenser) at all times, here represented by a fluence rate contour that is non-parallel to the rod. Considered at a certain speedBuilt-in at a certain distance h i And h j Two identical circulating objects passing all the way along the dispenser will be at specific positions a, respectively i (h i ) And A j (h j ) Find about by->Optimal fluence rate for defined irradiation time to address specific hot spots Ω i,λ . Obviously, the optical gradient is adjusted according to the optical coefficient of the circulating medium, the geometry of the container, the speed level and the nature of the flow (laminar, turbulent, pulsatile).
Fig. 19b: the wavelength combinations of non-uniform emissivity are illustrated along with the continuous non-uniform longitudinal emissivity from the cylindrical dispenser. In some cases where a particular hotspot cannot be selected, for example, due to a mismatch between the constraint illumination time and the accessible fluence rate, an effective (λ) can be used i ) And not effective (lambda) j ) The combination of wavelength illumination bypasses this problem. In this scheme, in the case of any hot spot where any kind of cycle can be selected, the equal doses of the two wavelengths can be parallel, and then sequential or simultaneous uniform irradiation can be used to obtain an effective PBM effect. In contrast, if a hotspot of a certain cyclic object can be selected, non-uniform irradiation must be considered to optimally process all kinds of cyclic objects.
Fig. 19c: adjustment of the emissivity of the uniform longitudinal dispenser within the balloon. Will be(2 cm bars defined by radiolabels) are packaged into balloon-based catheters. The shape and size of the balloon is limited by the emissivity shape of the RDAnd (5) setting. In this case, the circulating objects passing near the balloon will be exposed to different fluence rates, as the distance within the dispenser is adjusted by adjusting the balloon diameter.
Fig. 20: cylindrical distributor for pig chest fluoroscopy display70 And) wherein the arrow positions the radiolabel defining the rod (7 cm). The rod starts from the superior vena cava, then passes through the right atrium, and ends in the inferior vena cava, as shown in fig. 15. The dispenser was placed following the procedure described in example 13, except that the catheter used was a peelable catheter that could be removed with the optical dispenser located only in the central venous line. The optical dispenser may allow for a duration of several days for long-term irradiation.
Fig. 21: irradiation planning schemes using hot spot "lines" at 689 nm. In FIG. 4, for a composition comprising 0.5 to 20mW.cm -2 A relatively efficient line appears at 40 s. This can be used to optimize irradiation treatment time by increasing the treatment depth per irradiation time. It is well known that fluence rates emanating from a gap longitudinal uniform distributor placed in a semi-infinite medium can be approximated by analytical expressions based on a second type of bessel function. Fig. 21 shows the optical coefficient (ua=0.17 mm -1 :ueff=0.88mm -1 ) A treatment regimen of the evolution of the fluence rate defined internally perpendicular to the dispenser axis. Between 0 and 40s, 2.8mW.cm -1 Is coupled to the dispenser, which causes 20mW.cm near the surface of the dispenser -2 To a fluence rate of about 0.5mW.cm at-3.5 mm -2 Is a function of the integrated flux rate of (a). Between 40s and 80s, the optical power (multiplication factor P) was adjusted to 100mW.cm -1 So as to obtain 20mW.cm at 3.5mm -2 And the fluence rate at-7 mm reaches 0.5mW.cm -2 . Thus, using this hot spot line, in this case, the treatment depth was 7mm within a treatment time of 80 s.
Fig. 22: selection of a combined hot spot using the same wavelength at its particular illuminationA graphical representation of different portions of a biological subject being treated simultaneously over time. Based on the same simulation as described in fig. 21, in which a longitudinal dispenser is placed in the myocardium, the graph shows the evolution of the fluence rate of the continuous optical power applied over the depth of the tissue over the time indicated by the inset. Using hot spots Ω i,689 =(20±1mW.cm -2 The method comprises the steps of carrying out a first treatment on the surface of the 60±1 s) with another hot spot Ω, for example, exhibiting a lower fluence rate but a multiple of the irradiation time j,689 =(3±1.6mW.cm -2 The method comprises the steps of carrying out a first treatment on the surface of the 180±1 s) to treat the joint surface layer successfully every 60s (using Ω i,689 ) While in parallel the second region of depth is accumulating therapy (the portion of fluence rate marked with black underline). During period a, three surface layers were treated (by every 60s relative to Ω i,689 Increasing the optical power) (illumination time projected on the lower graph), whereas the depth area will receive a range of 3±1.6mw.cm -2 Is a continuous 3 x 60s. Since a portion of the depth region is subsequently received 180s, the optical power of this period is defined to avoid irradiating a portion that has been received 180 s. Then, as shown, the starting optical power of period B is defined as continuing Ω j,689 This results in another part of the object being subjected to Ω i,689 。
Fig. 20: cylindrical distributor for pig chest fluoroscopy display70 And) wherein the arrow positions the radiolabel defining the rod (7 cm). The rod starts from the superior vena cava, then passes through the right atrium, and ends in the inferior vena cava, as shown in fig. 15. The dispenser was placed following the procedure described in example 13, except that the catheter used was a peelable catheter that could be removed and the optical dispenser was located only in the central venous line. The optical dispenser may allow for a duration of several days for long-term irradiation.
Fig. 21: the illumination planning scheme illustrates how the illumination time can be minimized with a "long" cylindrical light distributor inserted into a "large" biological object using the "line" hot spot seen in fig. 4 a. In this geometry, the fluence rate varies with distance from the surface of the light distributor The evolution of (c) can be modeled by an analytical expression comprising a second class of bessel functions. For two different linear power densities expressed in mW/cm of the length of the optical splitter, the following optical coefficients (μ) for the biological object a =0.17mm -1 :μ eff =0.88mm -1 ) The evolution of the fluence rate as a function of distance as described above is shown. The first (2.8 mW/cm), using 40s, causes 20mW/cm at the light distributor surface 2 And at a distance of 3.5mm, the fluence rate is about 0.5mW/cm 2 . The second linear power density (100 mW/cm) was applied for between 40 and 80s, thus resulting in 20mW/cm at 3.5mm 2 And at 7mm the value was 0.5mW/cm 2 . Thus, the hot spot line was used for treatment for 80s with a treatment depth of 7mm.
Fig. 22: the use of two hot spots in combination (corresponding to surface Ω i,689 And omega j,689 ) To simultaneously treat illustrations of different depths of a biological object with one wavelength. Considering the geometric and optical conditions corresponding to fig. 21, the evolution of fluence rate with depth is shown for different linear power densities applied sequentially. Use of hotspots (Ω) i,689 :20±1mW.cm -2 ;60±1s)、(Ω j,689 :3±1.6mW.cm -2 The method comprises the steps of carrying out a first treatment on the surface of the 180±1 s), four layers were treated during two irradiation periods (a and B). During period a, hot spot Ω is used by increasing the linear power density by steps of 60s up to 180s i,689 To treat two layers while the other two layers are using the hot spot omega j,689 Treatment is performed at that time. As shown in the upper right hand corner of fig. 22, the total treatment time was 360s. It should be noted that the linear power density for period B is defined in such a way that the two treatment layers lying between 1 and about 3mm are continuous.
Fig. 23: this figure is a summary of figure 22 when applied simultaneously at two wavelengths exhibiting different penetration depths in tissue. Thus, the combined use of these two wavelengths can reduce the processing time mentioned in fig. 22 by a factor of 2.
Fig. 24a: the figure shows the normalized fluence rate around a tapered light distributor of length 7cm, expressed in (mW/cm) 2 ) The letter/(mW/cm) indicates that the tapered light distributor is surrounded by a light guide having an optical property (. Mu.) corresponding to blood a =0.25mm -1 ,μ eff =1.07mm -1 ) Is a fluid of (a) a fluid of (b). The arrow indicates the blood volume element (blood volume element) propagating according to a trajectory parallel to the axis of the optical splitter, which trajectory is at a distance of 4mm from this axis. The figure illustrates that the blood volume element will be exposed to a desired normalized fluence rate independent of the location of the blood volume element.
Fig. 24b: the figure shows the same situation as in fig. 24a, but with the blood volume element propagating on the surface of the cone-shaped light distributor.
Fig. 25a: blood glucose quantification between the beginning and end of a hypoxemia event. PBM irradiation in deoxygenated blood during hypoxia significantly reduces blood glucose levels in blood.
Fig. 25b: during PBM irradiation in normoxic pulmonary arteries, the clark probe monitors arterial partial pressure in the aorta.
Detailed Description
The inventors have shown that the light dosimetry (fluence rate [ mW/cm) 2 ]The method comprises the steps of carrying out a first treatment on the surface of the Light dose [ J/cm ] 2 ]) And spectroscopy (wavelength) and control of the duration and time of irradiation are critical to cause optimal PBM effects. This observation is very important because it is known that the PBM effect is bimodal (sometimes referred to as biphasic), i.e. that fluence rates and/or light doses that are too high or too low significantly reduce the PBM effect, and therefore are often associated with the artdt-Schultz rule observed in pharmacology. Many groups studying various "standard" effects (mitochondrial membrane potential; ATP production; etc.) reported such bimodal responses [ Huang 2009; hamlin 2017; hamblin 2018]。
The effect of PBM on the endogenous production of PpIX in different cell lines, including glioma cells and Human Cardiomyocytes (HCM), was studied, and the inventors found that both fluence rate and irradiation time must be applied in a controlled manner. For a given illumination in each part of the biological object volume for optimizing the PBM effect, these two parameters have to be applied with specific values. Contrary to what is reported in the art, the inventors found that the bimodal effect of PBM was observed only for a specific set of these parameters. These parameter sets are defined in this document as "hot spots" (fig. 4a and 4 b). Furthermore, the inventors have shown that some of these hot spots are independent of wavelength.
It was also determined that the optical properties of biological tissue (described primarily by its absorption and scattering coefficients) have a significant impact on the propagation of light around the light source [ Tuchin,2015; hamlin 2017; hammblin 2018]. In general, the fluence rate (and light dose) decreases with distance from the light source due to absorption and scattering of light in the tissue (see fig. 1). Thus, in most cases, fluence rates and/or light doses in tissue will never be optimal simultaneously in different locations in tissue treated by PBM. The existence and the existence of the parameter hot spot are as follows: i) The combination of non-uniform distribution of light in tissue treated by PBM, and ii) very limited control of light delivery and dosimetry by most research or clinical teams active in this field, explains the limited and contradictory results reported in the literature [ Chung 2012]. This also explains why PBMT is currently poorly applied.
It is an object of the present invention to provide an improved PBM for use in the treatment of biological objects, such as tissues, circulating blood and/or lymph.
It is another object of the present invention to provide an efficient treatment of ischemia reperfusion injury, such as Myocardial Infarction (MI), by PBM applied in the above and below mentioned conditions and methods.
It is another object of the present invention to provide an efficient treatment of fibrillation, including atrial fibrillation, by the PBM applied in the conditions and methods mentioned above and below.
It is another object of the present invention to provide an efficient PBM-based treatment of metabolic disorders (e.g., type 2 diabetes, liver disease or hormone secretion) under the conditions and methods described above and below.
It is another object of the present invention to provide an efficient treatment of systemic inflammatory or exacerbated systemic immune response by PBM applied in the conditions and methods mentioned above and below.
It is another object of the present invention to provide an efficient PBM-based treatment to maintain systemic homeostasis during hypoxia and/or anoxia, under the conditions and methods described above and below.
It is another object of the present invention to provide efficient methods in cell-based therapies, particularly to increase proliferation rates of stem cells and trigger cell differentiation.
It is another object of the present invention to provide efficient PpIX-based treatment/diagnosis by fluorescence imaging PpIX, for example in photodynamic therapy or in cancer detection. Embodiments of the invention relate to: helmets using integrated light emitting diodes, which induce PBM irradiation through the skull over specific areas of the brain prior to photodynamic detection (PDD) or photodynamic therapy (PDT) procedures for controlling cancer.
It is another object of the invention to increase and homogenize the endogenous production of PpIX in plants and larvae. One example of such a method is to increase the efficacy of phototoxic effects induced in grasses/larvae.
It is another object of the present invention to provide for an efficient treatment of a condition by PBMT based on monitoring of metabolic activity. Such monitoring is based on frequency analysis of parameters reflecting metabolic activity, which enables to adjust radiometric parameters (fluence rate, irradiation time, light dose … …) and spectral (wavelength) parameters in such a way as to maximize the PBM effect. Such monitoring may also be used to evaluate the state of metabolic activity to determine the optimal light application moment. Embodiments of the present invention relate to the use of standard probes to measure biochemical parameters reflecting physiology of metabolic activity. As described below, such probes include thermocouples and Clark pO 2 The probe or fiber-optic based probe measures these parameters. The signals delivered by these probes are then processed by a dedicated unit to perform frequency analysis, enabling extraction of parameters providing information about the PBM effects and metabolic activity.
The above object is achieved by the device and method of the invention as defined in the claims.
Advantageously, the device and method according to the invention is characterized in that the PBM effect is caused continuously in each part of the volume of the biological object by the generation of a specific fluence rate during a specific time corresponding to a specific "hot spot" as a selection condition (see below).
An illustrative embodiment of the present invention includes using one or more light sources coupled to one or more light distributors to apply a particular fluence rate during a particular time corresponding to one or more "hot spots" presented in fig. 4a and 4b to increase metabolism in the tissue/condition of interest referred to below.
The present invention also optionally includes an apparatus and method for predicting the time of application of PBM to a biological object based on frequency analysis of fluctuations in parameters reflecting metabolic activity (differential analysis of time signals (past integration or present derivative)) or based on artificial intelligence prediction methods reflecting one or more parameters of the PBM effect or metabolic activity of the biological object.
Optionally, the light power delivered by the device, the illumination time and the moment of change of the PBM application with respect to the metabolic activity are adjusted based on the feedback observables (see the list given below) to optimize the PBM effect.
Observable feedback:
a) Temperature.
Fig. 2 presents the evolution of the temperature measured with a thermocouple and a probe for measuring the Oxygen Consumption Rate (OCR) reflecting metabolic activity in an experimental setup developed by the inventors. The setup included a single layer of Human Cardiomyocytes (HCM) at the bottom of a petri dish covered with a 15mm thick layer of physiological water. Thermocouple and method for measuring OCR and partial pressure of oxygen (pO) 2 ) Is located 1mm above the cell monolayer.
As can be seen from FIG. 2, when pO 2 And therefore a significant and easily measurable change in temperature is observed when OCR is changed. The temperature increases with increasing OCR activity. Interestingly, in pO 2 The OCR and high frequency oscillations of temperature observed after the maximum are in phase and synchronized.
Thus, measuring the temperature provides observable feedback to monitor and/or adjust the light dose for the PBM. Measuring the temperature also allows to determine the optimal PBM irradiation time with respect to metabolic changes.
b) Reflecting participationTissue in the redox state of the metabolized enzyme autofluoresces.
Oxidation is the primary process by which the necessary energy is generated in the cell. It may occur under aerobic or anaerobic conditions. In many cases, biological oxidation begins with substrate dehydrogenation, i.e., the replacement of two hydrogen atoms, while coenzymes such as nad+, nadp+ and FAD act as acceptors for these atoms. Because of the low intracellular concentration of these coenzymes, they must be recovered by reoxidation. Thus, these coenzymes act as the primary donor and acceptor in oxidative phosphorylation (OXPHOS) [ ferroesi, 2012 ] ]. Due to the binding of NADH and FAD to a number of enzymes involved in metabolic pathways [ Alberts,2002 ]]Thus, when the cell switches its metabolism, the relative ratio between NADH and FAD binding sites will also change [ Banerjee,1989 ]]. Thus, the cell pair produced by PBM can be monitored for O 2 The response to changes in levels (changes in metabolic activity) was observed for their effects on FAD and NADH.
These coenzymes can be studied nondestructively and their autofluorescence observed, i.e. without the addition of exogenous probes [ Ramanujam,2001]. One of the most common optical techniques for providing information about the metabolic state of cells is based on determining the redox ratio of FAD and NADH by fluorescence spectroscopy (in particular time resolved fluorescence spectroscopy [ Skala,2007; skala,2010; kalina, 2016; walsh,2013 ]); walsh,2012; blackberry, 2016], a field corresponding to the expertise of the inventor for more than twenty years [ Wagni res,1998]. For example, in cancer cells, an increase in cellular metabolism is generally indicated by a decrease in redox ratio [ Chance,1989].
Thus, steady state and/or time resolved fluorescence spectroscopy (or imaging) of tissue autofluorescence is a interesting feedback observability for monitoring or adjusting the light dose for PBM. Interestingly, this approach was combined with exogenous pO based on molecular probes (PPIX or kalina et al 2 Probe [ kalinia, 2016 ]]) Or direct O of time-resolved luminescence spectrum of interstitial Clark Probe 2 Sensing is used in combination to provide unique information about the PBM effect. Monitoring these parameters is minimally invasive and rapid.
c) Blood vesselAssessment of hemoglobin saturation.
Under normal conditions, the body maintains a stable oxygen saturation level to a large extent through chemical processes of aerobic metabolism associated with respiration. However, it is well known that hemoglobin saturation varies due to different metabolic activities.
Since many methods are well established to measure hemoglobin saturation, particularly peripheral or central venous saturation, which is known to reflect cardiac output other than septic shock, it is of great interest to apply such methods to monitor changes in metabolic activity caused by PBM.
In addition, since various gases are endogenously produced and diffuse in tissues and circulating blood, and can bind to various kinds of metallic proteins exhibiting strong light absorption bands, for example, NO or H 2 S can combine with deoxyhemoglobin to produce nitrosyl or sulfur or carboxin that reduces the level of available deoxyhemoglobin, and since PBM can cause photodissociation (photolysis) of the metallo-proteins to hemoglobin, especially nitrosyl [ Lohr,2009 ]Methemoglobin is formed simultaneously and changes due to these different forms of "hemoglobin" can be measured (by light absorption measurement [ Van leeuwen,2017]) It is therefore of great interest to monitor changes in metabolic activity caused by PBM by assessing these different metalloprotein complexes.
3 - d) pH and/or bicarbonate (HCO) level.
Glycolysis is a well known metabolic pathway that converts glucose to pyruvate, which leads to acidification of the extracellular surrounding medium. This acidification is typically caused by lactate excretion following conversion of lactate from pyruvate [ Wu,2007].
Since many methods are well established to measure pH or bicarbonate levels in tissue or circulating blood, it is of great interest to apply such methods to monitor changes in metabolic activity caused by PBM.
Since tissue (or saliva) lactate concentration can be continuously assessed by a minimally invasive device such as a subcutaneous microneedle [ Tsurukoa,2016] or in the oral cavity, this method can be used to monitor changes in metabolic activity caused by PBM.
e) Concentration of ROS.
Reactive Oxygen Species (ROS) are chemically reactive oxygen-containing chemical species. Examples include peroxides, superoxides, hydroxyl radicals, singlet oxygen ([ Hayyan,2016 ]), and alpha-oxygen. In the biological context, ROS are formed as natural byproducts of normal oxygen metabolism and have an important role in cell signaling and homeostasis [ Devasagayam,2004]. ROS are produced during various biochemical reactions within cells and within organelles (e.g., mitochondria, peroxisomes, and endoplasmic reticulum).
The effects of ROS on cellular metabolism are well documented in various categories [ Nachiappan,2010]. These include not only roles in apoptosis (programmed cell death), but also positive roles such as the induction of host defense genes and the mobilization of ion transport systems. This implies that they control cellular functions. In particular, platelets involved in wound repair and blood homeostasis release ROS to recruit additional platelets to the site of injury. These also provide a link to the adaptive immune system by recruiting leukocytes.
Abnormal levels of ROS have been implicated in a number of pathologies through the strong regulation of various biological cascades [ Sies,2020]. Interestingly, ROS levels are for cell reprogramming [ Bigarella,2014; zhou,2016] and tissue remodeling are also native. For example, their kinetics of production depend on a broad spectrum of external or internal repetitive stimuli, such as hormone secretion or mechanical forces (e.g. vascular shear stress), which directly affect tissue behaviour and properties [ Hwang,2003; brandes,2014], and ultimately affect phenotypic aspects.
Since many methods are well established to measure ROS in tissues, it is of interest to apply such methods to monitor changes in metabolic activity caused by PBM.
Since ROS and Reactive Nitrogen Species (RNS) are intrinsically intricate [ moldazieva, 2018], and since many methods of assessing RNS are well established [ grocery, 2016], the term reactive oxygen species and reactive nitrogen RONS will be used herein. Indeed, in a broad sense, the term shall be active oxygen, active nitrogen and sulfur species (RONSS).
2 f) Content of HS.
Hydrogen sulfide (H) 2 S) exert a wide range of effects on the whole organism. It is an epigenetic regulator, in particular by DNA demethylation to cause histone modification, a process that allows cell differentiation [ Yang,2015 ]]. Which is indispensable in the aging process of aerobic organisms by maintaining high levels of mitochondrial DNA copy number [ Li,2015 ]]And activation by sirtuin 1 is essential in the aging process. Interestingly, H 2 S is the only species that is both a substrate and an inhibitor of intra-mitochondrial OXPHOS based on its concentration [ Szabo,2014]This is probably consistent with the well-known observation that exogenous H 2 S-inhalation causes a state of similar death in small mammals, called artificial hibernation or hypometabolism [ Blackstone,2005]. H is well known 2 S prevents a number of heart diseases including heart failure caused by pressure overload [ Snijder,2015 ] ]. This supports the hypothesis that endogenous H 2 S is a regulator of energy production in mammalian cells, in particular during stress conditions, which enables the cells to cope with energy demands in case of an oxygen deficiency [ Fu,2012 ]]。
Furthermore, we observed in ovo hypoxia reoxygenation in fertilized chicken eggs. This study was performed by combining H 2 The S microprobe was gently placed over the ventricle or dorsal aorta of the chicken. We observed H 2 The S level increases significantly during hypoxia (transient) arrest (or when the heart beats very slowly) and decreases upon re-beating. Thus, it appears that blood flow is through elimination of H 2 Endogenous production of S plays a role, H 2 S can bind deoxyhemoglobin to form and spread sulfur hemoglobin.
Since many methods can be well established to measure H in tissue 2 S[Olson,2012]Thus, this method is applied to monitor generation caused by PBMChanges in metabolic activity are of great interest.
2 g) Hydrogen selenide (HSe) levels.
Along with oxygen and sulfur, selenium (H) 2 Se) belong to the chalcogen group and have similar excretion and metabolic pathways. Similar to H 2 S,H 2 Se is an endogenous small gas molecule that can cause pseudoid death states and shows reperfusion injury protection [ Iwata,2015 ]. Which reversibly binds to COX inhibiting mitochondrial respiration and is thought to bind to H 2 S, NO and carbon monoxide (CO) together [ Kuganesan,2019 ]]. Furthermore, glutathione peroxidase is incorporated as a glutathione peroxidase in numerous selenoprotein oxidoreductases, which are critical for maintaining redox state homeostasis in health and disease, and its deficiency causes a substantial increase in ROS, which is suspected to be an important cause of cancer and CVD [ Bleys,2008]。
Since many methods are well established to measure H in tissue 2 Se or selenium in serum, it is therefore of great interest to apply this method to monitor changes in metabolic activity caused by PBM.
h) Ion concentration.
Ions play an important role in the metabolism of all organisms, which is reflected in the various chemical reactions in which they are involved [ van Vliet,2001]. Ions are cofactors for enzymes, catalyzing basic functions such as electron transport, redox reactions, and energy metabolism; and they are also essential for maintaining the osmotic pressure of the cells. Ion homeostasis is critical for all living organisms, as ion confinement and ion overload both delay growth and can lead to cell death.
Since many methods are well established to measure ions (particularly calcium, potassium, chloride and/or hydrosulfide ions) in tissues, it is of great interest to apply such methods to monitor changes in metabolic activity caused by PBM.
i) Cytochrome levels, including cytochrome c oxidase, were monitored by NIRS.
It is well known that broadband near infrared spectroscopy (NIRS) can be used to monitor changes in concentration of cytochrome oxidation states, such as cytochrome-c-oxidase (Δoxcco), which plays a key role in mitochondrial respiration [ Roever,2017].
Since different methods are well established for measuring Δoxcco in tissues (or other cytochromes involved in metabolism), it is of interest to apply these methods (including NIRS) to monitor changes in metabolic activity caused by PBM.
j) Using medical (functional) imaging techniques (MRS "magnetic resonance spectroscopy"; MRI "magnetic resonance imaging"; NMR "Nuclear magnetic Co-ordination
Vibrating "; PET "positron emission tomography"; EPR "electron paramagnetic resonance"; SPECT single photon emission computed tomography
Drawing "; BOLD "blood oxygen level dependence"; NIRS "near infrared spectrum").
Metabolic imaging focuses on and targets changes in metabolic pathways to characterize various clinical conditions. Most molecular imaging techniques are based on PET and MRS, including conventional techniques in thermal equilibrium 1 H and 13 cMRS and hyperpolarized magnetic resonance imaging (HP MRI). Di Gialleonado et al review metabolic pathways altered in many pathological conditions and corresponding probes and techniques for studying these alterations [ Di Gialleonado, 2016 ]]. Furthermore, fuss et al [ Fuss,2016 ]]The use of medical imaging to address various conditions in humans is described.
Since many metabolic imaging-based methods are well established to assess metabolism, it is of great interest to apply these methods (including functional metabolic imaging) to monitor changes in metabolic activity caused by PBM.
k) Vascular tone and vasomotor.
Vascular tone refers to the degree of constriction undergone by a blood vessel relative to its maximum expanded state. All arterial and venous vessels under basal conditions have a degree of smooth muscle contraction between the balance of the contracting and expanding muscle effects, which determines the diameter of the vessel, e.g. vascular resistance to adapt/regulate blood flow and pressure. Basal vascular tone varies between the large circulation, the microcirculation and the organs. Certain organs have greater vasodilatory capacity (e.g., myocardium, skeletal muscle, skin, visceral circulation) and therefore high vascular tone, while other organs have relatively lower vasodilatory capacity (e.g., brain and renal circulation) and therefore low vascular tone.
The degree of vascular tone is regulated differently between macroscopic (arteries, veins) and microscopic (arterioles, venules, capillaries). Notably, even though tone may be regulated by extrinsic factors (nerves, circulatory metabolites), blood vessels exhibit spontaneous oscillations (vasomotor), causing blood flow movements [ Aalkaejer,2011]. Thus, analysis of vascular tone through dependence of the tone in various actuators from local to systemic can provide insight into metabolic activity and can reflect the degree of aging [ Bentov,2015] and many pathophysiological conditions such as ulcer risk, type 2 diabetes [ Smirnova,2013], endothelial dysfunction or hypertension [ Ticcinelli,2017], renal disease [ Loutzenhiser,2002] [ Carlstrom,2015] or metabolic syndrome [ Walther,2015]. Furthermore, assessment of the endothelial function of the cutaneous microvasculature was used as a diagnostic and prognostic symptom of CVD [ Hellman,2015].
Since many methods are well established to assess vascular tone and vasoconstriction, such as video capillary microscopy, plethysmography [ Tamura,2019], laser doppler flow meters, pressure measurements such as by Cutaneous Vascular Conduction (CVC) or time-frequency analysis, and since from a dynamic point of view all the cardiovascular system is considered to be a single entity coupled to an oscillator [ Shiogai,2010], any method capable of assessing changes in metabolic activity caused by PBM, including Heart Rate Variability (HRV) giving information about the autonomic nervous system by ECG or by Phonocardiogram (PCG) [ heart sound measurement of Alvarez, 2014], is of great interest 2018. As observed by the inventors during surgery, respiratory frequency variability (RFI) [ stevanovska,2007] or ballistocardiography is of great interest to monitor changes in metabolic activity caused by PBM.
l) electromagnetic endogenous signalIs used.
Electrocardiography (ECG), electroencephalogram (EEG) and Electromyography (EMG) are standard measurements of electrical activity of heart, brain and muscle metabolism, respectively. Novel ECG analysis based on signal computation classification [ Patidar,2015] is expected to be a tool for cardiac diagnosis, in particular, it is possible to understand in depth coronary artery diseases [ Kumar,2017], [ Acharia,2017], arrhythmias and ischemic diseases [ Bhoi,2017]. The same type of analysis was performed on EEG, showing interesting results of seizures (the most common brain disease) [ Bhattacharyya,2018].
Since many methods are well established to monitor these electromagnetic endogenous signals, methods that are capable of assessing changes in metabolic activity caused by PBM are of great interest.
m) use of bioimpedance signals.
It can be used clinically to measure various physiological parameters [ Petterson,2016]. This method is used for cardiac pacemakers such as Ensite from St Jude Medical, optiVol from Medtronic, and closed-loop stimulation from biotronik.
Since many methods are well established to measure bioelectrical impedance in tissue or directly on skin, any of these methods that are capable of assessing changes in metabolic activity caused by PBM are of great interest.
n) the presence of a marker in the circulating blood.
Long lists of circulating markers of interest that monitor light dose during PBM include metabolites (succinate, pyruvate, etc.), clotting factors, apoptosis factors, (pro-and anti-) inflammatory factors, as well as liver factors, mitochondrial cytokines (mitokins), or isolated mitochondrial levels, for example. It should be noted that only a few of these are listed here.
Blood glucose level: many conditions are associated with deregulation of circulating glucose levels, which can directly lead to systemic metabolic disorders, as in the case of diabetes. Therefore, monitoring changes in metabolic activity by assessing blood glucose is of great interest.
Succinate: succinate is a key intermediate of the tricarboxylic acid cycle (TCA) cycle, playing an important role in anabolic and catabolic pathways. Furthermore, it is significantly associated with reperfusion injury [ choucani 2014]. Mitochondria are a physiological source of succinic acid, but accumulated succinic acid may be transported into the cytosol and then into the circulating blood. This TCA cycle intermediate links the intracellular metabolic state and the intercellular signal, which is denoted [ Tretter,2016]. Succinate levels in blood vary from 2 to 20 μm, where the concentration increases with hypoxia stress, pro-inflammatory stimuli, exercise or pathological conditions such as type 2 diabetes, obesity or ischemia reperfusion injury [ grimizzi, 2018]. Since circulating levels of succinic acid can be monitored by bioluminescence assays or raman spectroscopy, it is of great interest to evaluate changes in metabolic activity caused by PBM by circulating levels of succinic acid.
Lactate and Lactate Dehydrogenase (LDH): LDH is a common marker of cell damage and cell death. In addition, PBM can reduce LDH generated during anaerobic exercises [ Park,2017]. Therefore, it is of great interest to use these markers to assess changes in metabolic activity caused by PBM. Furthermore, the combination of LDH levels with aspartate Aminotransferase (AST) levels can be an effective indicator of body tissue damage. It should be noted that the lactic acid level can be estimated directly on saliva using a new air-metering method [ Tamura,2018].
Due to high levels of metabolic activity in inflammation or immune response, in particular the ability to alter its phenotype by immune cells, serum/plasma levels of immune/inflammatory markers, such as: mtDNA copies, leukocyte count, total antioxidant capacity, bicarbonate, malondialdehyde (MDA), uric acid, bilirubin; cytokine or chemokine marker levels, for example, such as interleukin IL2, IL6, IL7, IL10, IL18 or tnfα, and macrophage inflammatory protein 1- α, IP10, MCP1; and because lymphocyte T and/or monocyte M2 activation by flow cytometry is also of great interest.
Serum/plasma levels of thioredoxin: the level of this enzyme is elevated in infections, ischemia reperfusion, and other oxidative stresses. They are therefore good markers for monitoring oxidative stress. Thioredoxin plasma levels are also elevated in coronary spasmodic angina and other cardiovascular disease patients [ Nakamura,2004].
Cardiac markers: several established markers (myoglobin, creatine kinase isozymes, troponin I and T, B type natriuretic peptides, transaminases) are used clinically for diagnosing myocardial infarction and also for diagnosing other organ injuries. To a lesser extent, LDH, glycogen phosphorylase and recently ischemia modified albumin can be used for diagnosis in 30 minute assays [ Dasgupta,2014]. This is also the case for thioredoxin levels [ Jekell,2004].
Levels of circulating eNOS and NO or nitrite or nitrate: the levels of these compounds are important, especially for regulating systemic blood pressure and systemic homeostasis [ Wood,2013]. To begin with, the loop H can also be evaluated 2 S or sulfite or sulfate levels to monitor changes in metabolic activity caused by PBM.
Circulating mitochondria: recently it has been shown that cell free functional mitochondria are present in circulating blood. Furthermore, mitochondrial cytokines (mitokynes) are important in metabolic remodeling, especially in heart failure [ Duan,2019]. Therefore, monitoring changes in metabolic activity by assessing circulating mitochondrial levels or mitochondrial cytokine levels is of great interest.
o) optical mapping of cardiac electrical signals using voltage sensitive fluorescent dyes.
Although optical imaging of cardiac electrical signals using voltage sensitive fluorescent dyes (VSFs) has only been performed in experimental studies, since these VSFs have not been approved for clinical use, FDA approved dyes, such as indocyanine green (ICG) [ Martisiene,2016], exhibit voltage sensitivity in various tissues, thereby increasing the hope that electrical activity of cardiac tissue can be mapped clinically. Therefore, methods based on mapping (or locally evaluating using a "point measurement" system) cardiac electrical signals using voltage sensitive dyes to monitor/adjust the light dose during PBM are of great interest.
p) assessing various tissue oxygen using redox sensorsAnd a state of the reduced state.Since metabolism and redox reactions are intricate and since many methods evaluate metabolic activity based on measurements of redox sensor proteins, monitoring changes in metabolic activity caused by PBM with redox indicator probes is of great interest.
q) assessing the status of various tissues, including cardiac tissue, using ultrasound.
Ultrasonography is a well established method of examining heart tissue. Many parameters characterizing heart tissue and blood flow are typically obtained during an ultrasound examination.
Therefore, methods based on the use of ultrasound inspection to monitor the light dose during PBM are of great interest.
2 2 2 r) reflecting each using pO (and/or OCR) by measuring arterial partial pressure of oxygen (PaO) and partial pressure of inhaled oxygen (FiO)
Metabolic activity of the tissue and/or the whole body.
pO 2 Measurements can be readily made in exogenous or endogenous probes of different compartments (tissues or organs) or of different organelles within a cell. For example, such probes may be detected optically. Other techniques, such as EPR oximeter, polarographic electrodes or BOLD imaging, are of great interest for assessing changes in metabolic activity caused by PBM.
s) use of hemodynamic variables.
In the clinic, these variables must be evaluated in real time to monitor metabolic activity, especially in the case of cardiovascular injury. Such measurements relate mainly to arterial and venous gas pressure, cardiac output, stroke volume, capillary vessel pressure and systemic and pulmonary resistance. Therefore, it is of great interest to use these methods to assess changes in metabolic activity caused by PBM.
t) use of the Krebs cycle enzyme kinetics.
It is well known that the krebs cycle enzyme kinetics are good markers of metabolism, particularly for assessing the levels of mitochondrial proteins. For example, since the activity of a Gu Dingmei or succinate dehydrogenase is generally measured clinically, it is of great interest to use these methods to assess changes in metabolic activity caused by PBM.
w) PpIX level
Protoporphyrin IX is a precursor to many organometallic proteins, such as hemoglobin and chlorophyll. The inventors have shown that, PBM treated cells tend to increase their endogenous production of PpIX. Therefore, it is of great interest to use methods based on detecting PpIX levels to assess changes in metabolic activity caused by PBM. Since heme concentration is a feedback parameter in the PpIX endogenous production pathway, it is of great interest to extend to measure circulating hematocrit levels to assess changes in metabolic activity caused by PBM.
x) monitoring metabonomics and lipidomics, in particular oxyipine (oxyipine).
Oxylipidins are biologically active metabolites derived from the oxidation of polyunsaturated fatty acids. Furthermore, they play a key role in cardiovascular thrombosis and risk factor progression. Therefore, their monitoring is of great interest.
y) glycoprotein levels
Glycoproteins, including proteins and carbohydrate chains, are known to be involved in many physiological functions, including immunity. They possess a receptor signaling domain that recruits signaling molecules.
z) glycerol level
Glycerol can be used as a marker of apoptosis. One of the functions of glycerol is to act as a chemical partner. In particular, it has the ability to enhance expression of apoptosis-regulating factors (bax).
aa) the assessment of the immunomodulatory effects caused by PBM can be monitored by pro-inflammatory circulating monocytes such as CD14, CD16, which can differentiate into dendritic cells. It can also be assessed by cytokine profile of macrophages.
ab) monitoring the basis of oxytocin levels. In the latter case, it has been shown to monitor oxytocin levels in the intensive care unit of premature infants as a relevant marker of pain.
Optionally, the optical power, duration of irradiation and application time of the PBM defined by the device are combined with the application of an exogenous stimulus, wherein the stimulus may be an agent that increases the effect of the PBM (see the list given below). It should be noted that the time between the administration of the exogenous agent and the PBM irradiation may take into account the duration of assimilation as well as the kinetics of activation of the agent.
The inventors have demonstrated that the combined administration of PBM with, in particular, an exogenous agent (sulfur donor) and a nitric oxide donor results in
Synergistic effect.
As the inventors have shown, co-administration of ALA with PBM increases the accumulation of PpIX and thus increases the level of endogenous PpIX. Thus, co-administration of ALA and light is of great interest for increasing the PBM effect. It should be noted that other exogenous agents may be combined in the PBM to increase its effect, as shown below.
As shown in fig. 3, the inventors have recently observed that angiogenesis observed on chick embryo chorioallantoic membrane (CAM) is even more stimulated when PBM is used in combination with FDA approved exogenous, sodium Thiosulfate (STS) (sulfur donor). This strongly suggests that the combination of PBM with exogenous such agents stimulates angiogenesis or metabolic activity more than PBM alone or such agents.
The assessment of these PBM effects on angiogenesis was performed using a method based on fluorescence angiography performed on CAM several days after PBM. FIG. 3 presents a general CAM fluorescence angiography (left panel), which was quantitatively characterized using image processing and analysis software developed by our laboratory [ Nowak-Sliwinska,2010]. The main objective of this development was to characterize the dynamic changes that occur in the capillary/vascular network of CAM between day 6 and day 12 embryo development (EDD), monitoring CAM vessels using an epifluorescence microscope equipped with a scientific camera after intravenous (iv) injection of fluorescent agent [ Nowak-Sliwinska,2010]. From the generated angiogram, 3 descriptors are extracted: per mm 2 Branch point number, average area of the vascular network grid, and average value of the third quartile of the grid area histogram. As shown in fig. 3, we The proof of concept results demonstrate that PBM significantly stimulates CAM angiogenesis. This effect is even more pronounced if PBM is combined with exogenous application of 175mM STS.
Interestingly, at the same time, the inventors monitored H on chick embryos 2 S and NO levels are observed in ovo, and topical application of STS causes a significant increase in NO over a long period of time (6 to 12 hours), whereas when PBM irradiation is performed 1-2 hours after STS application, the time to generate NO is significantly reduced, typically to one hour.
Since STS is clinically approved H 2 S donor [ Snijder,2015]It is used to prevent a number of heart conditions, as for H 2 S has been reported as [ Yu,2014 ]]Including heart failure by pressure overload caused by upregulation of endothelial Nitric Oxide (NO) synthase [ Kondo,2013]Renal ischemia/reperfusion injury [ Bos,2009 ]]Use of PBM in combination with H administration in conjunction with the above devices/protocols 2 S donors (e.g. STS or methylsulfonylmethane (MSM), or e.g. dithiothione, or other compounds exhibiting different H' S 2 S kinetic released donors) and/or NO donor substances, such as arginine, including NO itself, are of great interest.
Since cysteine is an important source of sulfides in human metabolism, the co-administration of such protein amino acids or derivatives thereof, e.g. selenocysteine, or synthetic forms such as N-acetylcysteine, is of great interest for enhancing the effect of PBM.
MSM is a naturally occurring organic sulfur compound that is used as an alternative source of bioactive sulfur. It is mainly used for anti-inflammatory treatment. It has been studied in animal models and in many human clinical trials [ Butawan,2017]. The antioxidant capacity of MSM is also recognized, and it has been proposed that the antioxidant mechanism acts indirectly through mitochondria, rather than directly at the chemical level [ Beilke,1987]. MSM is well tolerated by most people at doses up to 4 grams per day as an FDA approved substance with few side effects [ Butawan,2017]. Results of in vivo and in vitro studies indicate that MSM is responsible for oxidative stress and inflammatory cross-talk at the transcriptional and subcellular level [ Butawan,2017]. Interestingly, kim et alHuman ([ Kim, 2009)]) MSM has also been shown to reduce inducible expression of Nitric Oxide (NO) synthase (iNOS) and cyclooxygenase-2 (COX-2) by inhibiting nuclear factor- κB (NF- κB), a transcription factor involved in immune and cellular stress responses. This observation is very interesting because NO is a powerful vasodilator that is involved in many metabolic functions. With other gas conveyers (known as gas conveyers) [ Donald,2016 ] ]) As such, NO will have a specific effect on its local concentration and microenvironment [ Thomas,2015 ]]This may affect many different processes [ Rapozzi,2013; reeves,2009]. PBM has also been proposed to cause NO photodissociation from COX [ Karu,2005; lane,2006]. At the same time, NO photodissociation from other intracellular "reservoirs" (e.g., nitrosylated forms of myoglobin and hemoglobin) is also assumed [ Lohr,2009]. It has been established that NO production by mitochondrial NO synthase down regulates cellular respiration. Replacement of O by NO from COX 2 Can inhibit cellular respiration and ATP production [ Antunes,2004; cooper,2008]. Thus, PBM is believed to increase ATP production. Alternative and possibly parallel mechanisms explaining the release of PBM and/or increasing the bioavailability of NO may be related to the role of COX as nitrite reductase (single electron reduction of nitrite to NO), especially when O 2 Low partial pressure [ Ball,2011 ]]。
Taken together, these observations suggest that MSM has an indirect effect on the mitochondrial Electron Transport Chain (ETC) through its NO regulation. Furthermore, analysis of the literature shows that PBM is associated with NO donors (e.g.S-nitrosothiolsOr alkyl nitrite, including NO itself) causes a strong synergistic effect.
In addition, due to H 2 The interaction between S and NO can produce nitroxyl (HNO), which plays an effective role in oxidative stress and cardioprotection in the cardiovascular system, systole, angiotensin, and angiogenesis [ Nagpure,2016; wu 2018]Thus, co-administration of (H) NO with a nitroxyl donor, cimlanod or hexyl 1-nitrosocycloacetate is of great interest for increasing the PBM effect.
Ebselen is an FDA approved H 2 Se donors, which are interesting for increasing the PBM effect, as the inventors have discussed (page 13Point g).
As already mentioned, NAD + Is essential for redox reactions and it controls hundreds of key processes of energy metabolism for cell survival, rising and falling according to food intake, exercise and time of day. Thus, as vitamin B3, NAD in PBM + Administration of the donor is of great interest for increasing the PBM effect.
Other exogenous agents of interest for use in combination with PBM are:
curcumin, which is the main active ingredient of turmeric (l.), is known to have a variety of effects on both healthy and cancerous tissues. Notably, curcumin causes ER stress, resulting in unfolded protein responses, primary retrograde signaling, and calcium release, which disrupts the stability of mitochondrial compartments and causes apoptosis.
Dexmedetomidine, a well-known α2 agonist for anesthesia, has recently attracted interest because it is believed that dexmedetomidine pretreatment reduces myocardial ischemia/reperfusion injury by inhibiting mast cell degranulation. Similarly, EPO has shown a positive effect in lipopolysaccharide in ischemia reperfusion injury and arterial vascular injury in the kidney.
Ivermectin, approved by the FDA for the treatment of humans suffering from intestinal roundworm-like and onchocerciasis, both diseases caused by parasites. Furthermore, clinical evidence supports that the use of ivermectin reduces mortality in patients infected with SARS-CoV 2. The combination of ivermectin and PBM may reduce the dose of ivermectin, in particular reducing side effects.
Vigore as a source of nitrite in various forms (e.g. alkyl nitrite)
By extension, any exogenous agent known to regulate metabolism, for example, particularly by regulating ETC or ROS modulators to regulate metabolism in mitochondria, is of great interest to increase PBM effects. This is the case for Adenosine Diphosphate (ADP) which is known to increase OCR or for vitamin K, ketamine succinylcholine, acetylcholine and atropine, bradykinin. Other agents include catecholamines such as epinephrine, norepinephrine, or dopamine, opioids or various kinase modulators that activate various G proteins or various antioxidants and/or anti-inflammatory donors, such as resveratrol. Finally, targets for rapamycin or deacetylase modulators are of great interest to increase PBM effects.
To extend, due to temperature, exogenous or endogenous mechanical stress [ Li,2005; hwang 2003]Physical exercise as well as electrical stimulation, hyperoxia, hemostasis (remote pretreatment) are known to regulate metabolism, any exogenous stimulus or combination of environmental/physical/electrical or electromagnetic stimuli as applied to biological subjects are of great interest to increase PBM effects. For example, endogenous H is well known 2 The level of S is inversely related to temperature. The increase in temperature in situ can be considered as an indirect endogenous H 2 S donor, and conversely, an increase in situ temperature can be considered endogenous H 2 S inhibitors.
As observed by the inventors, the efficacy of PBM is not only dependent on the light dose [ J/m ] 2 ]And spectroscopy (wavelength), but surprisingly also on the fluence rate for a particular illumination time. For example, the inventors observed that the specific case shown in FIGS. 4a and 4b, a 3mW/cm period of 3 minutes was necessary 2 Irradiance (i.e. dose of 0.54J/cm) 2 ) The cells were irradiated (equal to the fluence rate in this particular environment consisting of cell cultures). The different irradiation times and/or irradiance do not cause any PBM effect, except for e.g. at 15mW/cm 2 By 40s or 25mW/cm during 22 seconds 2 "hot spots" observed under irradiance of (c). Interestingly, some of these hot spots are independent of wavelength, as a comparison of fig. 4a and 4b can conclude that the hot spots are present at the same location in terms of irradiance and illumination time.
This is a more complex illustration of the PBM response, i.e. the fluence rate and/or light dose being too high or too low, significantly reduces the PBM effect compared to the well known PBM bimodal effect. The inventors have also demonstrated that under certain conditions, there is no "neutralization" of the PBM effect by the excess dose/irradiation before and/or after application of the PBM at optimal conditions.
When in useThe inventors have also observed surprising results when the PBM is performed with a combination of wavelengths, wherein one of the wavelengths is ineffective when used alone. This is the case for 730nm, which wavelength is not effective when used alone, as shown in fig. 4 c. As can be seen from the figure, the wavelength of 689nm is 3mW/cm 2 Is effective for 180s of irradiation time at 9mW/cm 2 Is ineffective for irradiance applications. Surprisingly, 730nm (irradiance of 3mW/cm 2 For 180 s) and 689nm (irradiance of 9mW/cm 2 The simultaneous or sequential combination of irradiation for 180 s) produced a pronounced PBM effect, as evidenced by PpIX fluorescence intensity ratio (PBM/no PBM). These effects are comparable to the effects corresponding to the "hot spot" shown in fig. 4a and 4 b. Thus, a simultaneous or sequential combination of wavelengths in such a way that at least one of them is inactive (or poorly active) is of great interest to increase the PBM effect, especially when specific hot spots of active wavelengths are difficult to reach due to optical or geometrical limitations.
In fact, the optical properties of biological tissue (mainly by its absorption coefficient μ a And a lower scattering coefficient mu s ' described) has a significant effect on the propagation of light around the optical splitter, which is well established. In general, fluence rates (and light doses) decrease with distance from the light source due to absorption and scattering of light in the tissue for a given power (and illumination time). FIG. 5 illustrates that the optical element is in the "wide" (much larger than μ) eff -1 ) In the specific case of a semi-infinite sample of collimated illumination, how the fluence rate F (normalized by irradiance E) decreases with distance from the surface. Thus, fluence rates and light doses in tissue are never optimal at the same time at different locations of tissue treated by the PBM.
It should be noted that the geometry of the light distributor (illumination geometry) is adapted to the specific organ to be treated. For example, front side (wide area), balloon-based or interstitial irradiation using one or more optical fibers (see the commercial product of Medlight SA "http:// www.medlight.com/#", as an illustrative example) is specifically contemplated.
The inventors also established that the metabolic activity is based on reflectionIn particular using wavelet theory) to adjust the radiometry and innovation of spectral conditions used in PBMT. More precisely, they have an oxygen partial pressure (pO) of chick embryo chorioallantoic membrane (CAM) during PBM 2 ) Time-frequency analysis was performed.
It is well known that arterioles, in particular in the peripheral microcirculation, are regulated by complex metabolism [ Reglin,2014]pO to surrounding tissue 2 Reaction is intense [ Jackson,2016 ]]In which there is a low frequency oscillation of blood perfusion [ Kvandal,2006]。
Based on the use of commercially available Clark probesOX-needle, OX 100-Fast (Fast)) for pO in CAM during "long" (several hours) time 2 The local measurements performed, we calculated the slave pO 2 Is a frequency spectrum obtained by wavelet-based analysis. Wavelet analysis is a well known mathematical transformation that is capable of characterizing non-stationary frequencies during the measurement time. FIG. 6 (left middle) shows pO near the new CAM arterioles at embryonic day (EDD) 7 2 Is a typical measurement of (a). Here, the time signal (measurement time: -180 s) is mainly generated by superposition of the following 2 frequencies (see fig. 6, bottom left; vertical axis is frequency): heartbeat (-1 Hz) and myogenic tension (-0, 1 Hz) that represents the intrinsic activity of vascular smooth muscle.
H 2 S is an effective regulator of vascular tone [2012]It can be caused by administration of NaSH. We measured the H of CAM arterioles induced by topical application of NaSH (10. Mu.l, 1. Mu.M in physiological serum) using our Clark probe 2 S stimulation produced pO around 60mmHg 2 Strongly regulated. This modulation was observed at least for myogenic (0, 05Hz-0,15 Hz), endothelial nitric oxide synthase related frequency band (0.01 Hz-0.02 Hz) and endothelial nitric oxide synthase unrelated frequency band (0.005 Hz-0.01 Hz). Other lower bands are also activated, wherein this is clearly indicative of some of them being associated with prostaglandins or precursors from endothelial cellsProstacyclin release is associated.
Our innovation stems from our use of front side light distributors (850 nm,7mw cm -2 30 s) of PBM illumination performed on the CAM (see fig. 7). The adjustment ("dimming") of these frequencies (fig. 6 (upper right) and fig. 7) is obviously caused by the PBM.
In particular, bands 3, 5 and 6, and bands corresponding to undefined lower frequencies, appear to be totally or partially suppressed by the PBM (see fig. 6). Inhibition of band 3 (myogenic band) suggests that since this band is due to arteriole smooth muscle cells, it is caused by activation of NADPH Oxidase (NOX) and subsequent ROS production [ Nowicki,2001; li,2017]PBM inhibits NOX activity. Since the NOX superfamily plays an important role in inflammation and immune responses, where NOX in particular is involved in the metabolic turnover of leukocyte activation, our observations reveal that PBM regulates an important pathway of inflammation and is effective as an important immunomodulator. Furthermore, modulation of the myogenic tension in a biological subject by PBM can prevent many hypertensive lesions, as is the case in renal lesions [ Loutzenhiser,2002; moss,2016 ]. In summary, our results indicate that the parameters reflecting metabolic activity (e.g., pO 2 ) Can monitor the light dose and/or fluence rate for the PBM. It should be noted that for illustrative purposes, i.e., increasing the signal-to-noise ratio, the oscillations observed in FIGS. 6 and 7 are those observed by H 2 S. In fact, even in the absence of H 2 This oscillation also exists in the case of S.
Therefore, it is of great interest to adjust the radiometric and spectroscopic conditions used in PBM therapy based on frequency analysis of parameters reflecting metabolic activity.
This particular type of monitoring may be performed for two main purposes: i) The PBM light is applied at an optimal time with respect to metabolic "oscillations", or ii) the level of metabolic change caused by PBM is evaluated in a way that is optimal (to adapt to radiometry).
As just presented above, pO 2 Not the only parameter that is analyzed using wavelets or based on frequency to monitor the light dosimetry during PBM. Upper rowThe list (feedback observables list) describes other parameters of interest:
the inventors have also shown that the application time of light irradiation within a biological object is critical to cause significant PBM effects. These observations are important because biological objects are dynamic over a wide frequency scale of metabolic activities triggered by transient or conventional endogenous or exogenous factors. Notably, the inventors have shown that when light is applied at a specific time during the metabolic activity of glioma cells or HCM, the metabolic response of the cells is significantly differently modulated, thereby modulating the phenotype long-term response accordingly. The inventors also showed that using the in ovo chick embryo heart model during hypoxia/reoxygenation studies, when PBM irradiation was started just before reoxygenation, survival was significantly higher compared to when PBM was performed during long periods of ischemia before reoxygenation or after reoxygenation. Interestingly, under this condition, it was observed that reoxygenation caused a cardiac arrest during a time ranging from one second to several minutes. PBM modulation prior to reoxygenation significantly avoided this cardiac arrest. Thus, the inventors have shown that PBM restarts or regulates heart beat after hypoxic cardiac arrest or bradycardia or tachycardia occurs without observing the effects on a healthy beating heart. These in ovo observations have been confirmed by the inventors in vivo during an ischemic/reperfusion event caused by ligation of the coronary arteries of the pig heart.
The inventors also demonstrate that PBM can be used to modulate heart chicken embryos during hypoxia reoxygenation events.
One aspect of the invention is the use of the device or method to treat ischemia reperfusion injury, particularly those affecting the heart muscle, to reduce infarct size following an acute Myocardial Infarction (MI).
Based on chicken embryo hearts, the inventors developed an in ovo hypoxia reoxygenation experiment in which eggs were placed in a constant temperature air chamber in which the environment and embryo temperature and pO were continuously monitored 2 . For some experiments, small H 2 S, NO and pH probes are also positioned at different locations around the embryo heart or embryo tissue. The chamber was placed under a microscope for image recording. After a stabilization time (temperature stabilization), an anoxic environment is formed without any change in the ambient temperature by flushing nitrogen gas around the eggs during several tens of minutes, and the eggs are subsequently reoxygenated, as shown in fig. 8.
At Embryonic Development Day (EDD) 3, pure N was flushed during 45 minutes prior to embryo reoxygenation 2 Resulting in a mortality rate of more than 50% 48 hours after the end of the experiment. This experiment supports one aspect of the "reperfusion injury" mentioned as "oxygen paradox" in Latham et al (Latham, 1951), i.e., reperfusion may be fatal in some cases (Piper, 2000). In our case, and for isolated chicken heart embryos (Raddatz, 2010), reoxygenation causes bursts of Reactive Oxygen Species (ROS) and permanent or transient cardiac arrest, followed by irregular heartbeats (bradycardia, tachycardia). In our experiments, we observed that the embryo was photomodulated just prior to reperfusion when the embryo at EDD 3 underwent 45 minutes of hypoxia (671 or 806 nm,5mw. Cm 2 30 s) significantly avoided cardiac arrest and importantly increased 48 hour survival. Interestingly, if the light is applied too early or too late after reoxygenation, no such positive effect of PBM is observed. The last observation clearly shows that the time of application of light relative to reoxygenation is critical for producing beneficial results.
Thus, one application of great interest to the present invention includes the use of PBM delivered by our original medical devices and methods to treat lesions resulting from hypoxic reoxygenation events and lesions that are extended to ischemia reperfusion events.
The inventors have also shown that PBM can stimulate heartbeats after hypoxia non-permanent cardiac arrest in the chick embryo heart.
Oxygen supply to chicken embryos occurs primarily by diffusion across the shell and then through the embryo prior to Embryonic Development Day (EDD) 7. The heart beat and blood flow that can be observed from EDD 2 are mainly the stimulus for cardiovascular development. Embryos until day 5 flatten on a "surface" located directly under the albumin layer. Thus, it is easily accessible after removal of a portion of the shell. This is why, consistent with chicken embryogenesis, embryos ranging from EDD 2 to EDD 5 have been used as excellent models of developmental biology for decades, particularly in terms of cardiac and cardiac rhythm generation. The model was also used for hypoxia-reoxygenation studies [ Sedmera,2002], where their behavior was studied during and after hypoxia or hypoxia, but also during hypoxia-induced tachycardia, bradycardia or for fibrillation studies.
One interesting PBM effect observed by the inventors in-ovo hypoxia experiments is related to the positive effect of light, which enables restarting the heart after cardiac arrest. In fact, prolonged hypoxia can lead to a cardiac arrest, and the heart sometimes restarts beating briefly until an irreversible complete cardiac arrest occurs. The inventors observed that in most cases, consistent with resuscitation observations on ischemic pigs, PBM irradiation frequently restarted beating hearts following such cardiac arrest (fig. 9). Furthermore, based on frequency and phase shift analysis of the subchambers of the embryo heart (atrium, ventricle, outflow tract) beating, PBM irradiation stimulates the recovery of this frequency (especially harmonics) and the phase shift of the contraction between subchambers after hypoxia. This is of particular interest because this phase shift must be preserved to maintain the efficacy of the pump function (cardiac output). Thus, by monitoring the frequency and phase shift of the motion of the heart sub-chambers, as shown by the inventors, it is known that localized illumination of sub-chambers (particularly the atrium) is very sensitive to hypoxia and is of great interest in maintaining cardiac output.
This surprisingly positive effect of PBM strongly suggests that it triggers metabolic activity involving the heart beat, including after hypoxic cardiac arrest. PBM is of great interest, for example, in the treatment of conditions such as tremors (including atrial fibrillation) because it is known that PBM can reduce inflammation and promote metabolic activity.
By extension, since metabolism is subject to both autonomous (i.e. cell cycle independent [ Papaginankis, 2017 ]) and non-autonomous rhythms, as is the case for example with circadian rhythms [ Bailey,2014], the use of PBM light at specific times and/or frequencies to lock in, trigger and/or (re) synchronize metabolic oscillations is of great interest, especially for the treatment of various metabolic disorders, such as type 2 diabetes [ Petrenko,2020], metabolic conversion into aerobic glycolysis (Warbugg effect) in cancer cells [ Gatenby,2018] or liver disorders and diseases [ Zhong,2018 ].
The inventors have also shown that delivery of PBM light directly in the blood perfused large vessels (porcine pulmonary artery, vena cava) or in the right atrium containing deoxygenated blood can be used to modulate systemic hemodynamics and oxygen tension, resulting in anti-inflammatory, immunomodulating, anti-aggregation, endothelial cell and epithelial cell protection. Surprisingly, based on gas measurements performed in arterial and venous blood (using cobas b 123POC System Roche) This irradiation of deoxygenated blood maintains homeostasis during the long-term hypoxic event of the pig. In addition, these exposures maintain and stabilize functional hemodynamic variables, such as cardiac output, accompanied by heparinized NO probes (NO-NP) placed in the pulmonary artery or atrium, e.g., during the period of several ten minutes after PBM exposure ) An increase and stabilization of the systemic unsteady NO level measured internally. This effect is unexpected because it is generally believed that the lifetime of labile NO in blood is ten to hundred times shorter. Interestingly, there was no concomitant increase in the assessment of methemoglobin in venous or arterial gas during the experiment. Furthermore, the inventors have shown that PBM light delivered directly in the blood perfused large vessels (pulmonary arteries) or the right atrium containing deoxygenated blood can be used to control hypoxia, hemoglobin saturation, arterial and venous oxygen partial pressure associated with hypoxia. Furthermore, this approach can be used to maintain blood glucose levels (fig. 25 a) in order to significantly reduce the likelihood of causing systemic tissue damage, as is the case with Multiple Organ Failure (MOF) caused by blood glucose disorders.
Detailed description of the invention:
according to the results in FIGS. 4a and 4b showing the PBM effect on the ability of HCM cells to produce PpIX, 3mW/cm must be applied during 3 minutes 2 Is (or is strong)Degree) to maximize this effect. Since fluence rates are not uniform in volumetric (or 3D) tissue for a fixed irradiance, as shown in fig. 5, for a particular geometry and a particular optical coefficient, a medical device according to the invention preferably delivers irradiance that varies over time in such a way that all cells receive the optimal fluence rate during 3 minutes. In most cases, the illumination geometry will not change during the illumination process. Thus, irradiance is simply determined by the power of the irradiated tissue [ W ]Surface divided by the irradiation point [ m ] 2 ]Given. Although Yarosplavsky et al [ reference ]]A similar concept has been described, but one finding of the inventors mentioned herein is to determine specific values of fluence rate and illumination time that must be applied simultaneously.
Let us consider the specific case corresponding to the geometry and optical coefficient mentioned in fig. 5. Since the fluence rate F can be determined by a solution to the diffusion approximation (note: the assumption that the basis at the diffusion approximation must be satisfied, i.e.: i) μ a <<μs'; and ii) we are studying "far" from the light source and boundary (i.e. z>1/μ s ') fluence rate at position "z"; "k" is a factor generated by light backscattered by the tissue to increase fluence rate at the interface, e.g. Jacques [ Jacques,2010]Described).
F=k.E.e -μeff z Equation 1)
The only way to keep F constant (hereinafter F') to increase the value of z is to increase E. The statement results from the inversion of the last expression, written as:
E=(F’/k).e μeff z equation 2
Since each HCM cell must be operated at F' =3 mW/cm during 3 minutes 2 Another important concept is related to the tolerance affecting the fluence rate. If it is necessary to use a power of exactly 3mW/cm 2 Irradiating cells, the total treatment of the whole sample will take an infinitely long time, since the volume corresponding to these cells is equal to 0mm 3 (they are confined to a plane at depth "z", which has a depth equal to 0 mm) 3 Is the volume of (c). However, looking at FIG. 4a showsAt 3mW/cm 2 And an irradiance full width at half maximum (FWHM) of about 3.2mW/cm for a "peak" at 180s 2 I.e. fluence rate F' must be 3.+ -. 1.6mW/cm 2 In the range (hereinafter denoted as F '±Δf') to cause the optimal PBM effect after 180 s. This means that the HCM cells in which the best PBM effect is induced are not in the plane, but in the slice with a thickness Δz. The thickness Δz of the slice is given by:
because E= (F'/k). E μeff z We obtain:
Δz=ΔF’/μ eff f' equation 4
Therefore, Δz depends only on F ', ΔF' and μ eff 。
If the volume of tissue to be treated is in the range z 1 (proximal position) and z 2 (distal position), then the number "n" of different irradiance applied during 180s (hereinafter T) is equal to: z 2 -z 1 /Δz。
Thus, the spatial evolution of irradiance E is shown in fig. 10.
The temporal evolution of irradiance E (t) is (see fig. 11):
E(t)=(F’/k).e μeff.Δz.t/T =(F’/k).e ΔF’.t/F’.T equation 5
Wherein when 0 is<t<At T, E will be equal to (assuming the diffusion approximation equation is valid) F'/k.e ΔF’/2F’ When T<t<At 2T, equal to F'/k.e 3ΔF’/2F’ When 2T<t<At 3T, equal to F'/k.e 5ΔF’/2F’ When nT<t<(n+1) T, equal to F'/k.e (2n+1)ΔF’/ 2 F', where n=μ eff .F’.(z 2 –z 1 ) Δf' (see equation 6 below).
Thus, the treatment range is z 1 And z 2 The total time "t" required for tissue volume in between tot The method is as follows:
T.(z 2 -z 1 ) /deltaz. By explicit expression of Δz (equation 4), we get:
t tot =T(z 2 –z 1 )/(ΔF’/μ eff .F’)=T.μ eff .F’.(z 2 –z 1 ) Delta F' equation 6
Finally, it should be noted that, like F', T can be applied with a certain tolerance due to the FWHM of the PBM peak along the irradiation time axis (see fig. 4 a).
In summary, in this example, the device according to the invention is in the range 0 and t tot The irradiance E (t) is applied during the time in between, given by: e (t) = (F'/k) ·e ΔF’.t/F’.T 。
Since the device is powered by a specific power PW]Specific area of illuminated surface sm 2 ]We therefore get E (t) =p (t)/S.
Thus, the device is in the range of 0 and t tot The optical power P (t) is delivered during the time in between, given by:
P(t)=(S.F’/k).e ΔF’.t/F’.T equation 7
E (t) and t tot All parameters involved in the expression are for (known thickness z 2 -z 1 Determined by the specific organ and the irradiation geometry (of the surface S): in practice, F ', ΔF' and T are derived from FIG. 4a (for HCM), while k is derived from the tissue optical coefficient (known for the tissue of interest).
This detailed description of the best PBM effect for solving the entire volume of a particular hot spot of fig. 4a and 4b may be summarized as "hot spot line" or "hot spot surface" Ω iλ Where i represents a particular hot spot surface on the graph presented in fig. 4d at wavelength λ. Since the points presented in fig. 4a and 4b represent specific coordinates (fluence rate; illumination time), and since the points around the maximum of the hot spot may have reasonable efficacy, the hot spot may be described as being represented by a rectangle Ω iλ (ΔF’ iλ ;ΔT iλ ) Defined area: hot spot surface Ω iλ Is typically equal to omega in size iλ Average value of points in the interiorOr center of gravity, as shown in fig. 4 d. Can be defined to correspond to a specific omega iλ (which has a specific dimension DeltaF' iλ And DeltaT iλ ) In order to minimize the total treatment time within the concomitant reduction of the expected PBM effect, as described in more detail below. The minimization of cost algorithm can then define the optimal hot spot (spot, line or plane) based on user-defined parameter definitions, based on the treatment case (acute, chronic, severe, moderate) and the geometry of the treatment area, in particular by defining the maximum treatment time value and the expected minimum treatment efficacy level. For example, for the treatment of superficial wounds, it is optimal to use the point of hot spots, wherein in this case the treatment time is not too long due to the smaller wound depth. In the case of acute infarctions, however, the time is urgent and the treatment volume is also of considerable importance, the hot spot spots can be converted into Δf' iλ And/or DeltaT iλ The face of the relatively high hot spot is treated in the shortest time to treat as much total volume as possible. It should be noted that most hot spots are located at 0.2J.cm -2 To 1J.cm -2 But other hot spots may be present in the irradiation time range of the order of seconds, the corresponding fluence rate is per cm -2 Hundreds of mW.
In the description given above, the tissue is considered stationary, while the power of the light source varies over time to produce an optimal fluence rate in the target tissue during an optimal time. However, there are certain situations, for example in fluids comprising blood, where the geometry is dynamic, for example due to blood flow. In such cases, the power delivered by the light distributor may be stable (without time evolution), but the light pattern produced by the light distributor, combined with the fluid optical properties, may allow the fluence rate to be optimized in certain capacity elements due to the fluid flow. Therefore, it is necessary to introduce longitudinal variations in emissivity in such a way that the light dose and/or fluence rate is optimal in order to induce PBM effects at different locations of the moving fluid (e.g. blood). An illustrative example is presented in fig. 19a, where a non-uniform longitudinal light distributor is located in the center of a blood vessel. Due to the emissivity (W/cm of the optical distributor 2 ) Increase of the irradiation window along the sameAdditionally, a blood volume element located close to the surface of the dispenser will thus obtain the proper irradiance on the left side of the image, while a blood volume element located away from the surface will obtain the proper irradiance on the right side of the image. Thus, the whole blood volume will receive the optimal dosimetry as it moves along the cylindrical light distributor.
Based on the surprising results obtained by the inventors, which demonstrate that the effect resulting from the use of PBM effective wavelengths applied under suboptimal radiometric conditions can be optimized by the combined application of non-effective wavelengths, another PBMT scheme can be defined. An illustrative example (fig. 19 b) involves PBMT irradiation, where both the active and inactive wavelengths are delivered continuously. Wavelengths may also be delivered at the same location of the dispenser. The optimal optical longitudinal distribution profile depends on many parameters including vessel diameter (geometry), blood flow, its state (laminar, turbulent, pulsatile aspects … …) and blood optical properties. The device can be easily manufactured with minor changes to the process used to achieve a uniform cylindrical light distributor, or by designing a specific balloon catheter shape/size, as shown in fig. 19 c. The use of the balloon (inflation, irradiation, deflation) may be static or dynamic, just like the counterpulsation balloon used in the aorta, inflated or deflated during weeks in synchronization with the heartbeat. The time of flight (time of the subject around the rod) can also be adjusted to optimize PBM treatment. This may be done, for example, based on the regulation of cardiac output (using NG-monomethyl-L-arginine (L-NMMA), or by the inflation level or inflation/deflation cadence of a balloon-based catheter around the light distributor.
Example 1: treatment of myocardial ischemia-reperfusion
A detailed example of an apparatus according to the invention is presented in this example.
Such treatment of myocardial ischemia-reperfusion may be performed during:
1. during acute or chronic Myocardial Infarction (MI).
2. Aortic occlusion and cardiac arrest following extracorporeal circulation.
3. During organ transplantation (heart, lung or otherwise).
The light distribution route considered is:
1. interstitial (warp heart muscle)
2. Cavity (indoor)
3. Intravascular (intracoronary)
Medical device for warp and heart muscle
This involves implantation by the cardiac surgeon through the heart, after the acute phase of MI or during revascularization of the myocardium after aortic occlusion for more than 120 minutes under extracorporeal circulation or during heart transplantation, of a light distributor, preferably cylindrical and based on one or more optical fibers (fig. 12, 13 and 14 b).
These light distributors are placed in the diseased heart area (e.g. ischemic area) at the end of the surgery before or during coronary reperfusion.
These light distributors are placed according to the procedure described below:
1) The treatment region is located and estimated by:
a. macroscopic assessment of affected area (FIG. 14 a) (visual indicators: edema, akinesia, dyskinesia, vermilion appearance and/or use of characterization instruments)
b. Correlation with coronary angiography and ultrasound data corresponding to the following ischemic myocardial anatomical region (e.g., left ventricle):
i. front region (Anterior territory)
Side region (Lateral territory)
Lower region (Inferior territory)
2) Determining the number of light distributors required for light delivery and their relative positions based on the extent and accessibility of the ischemic area:
a. in situ consideration of the distribution of the coronary arteries to avoid their penetrative fixation (trans-fixation)
b. The light distributors are fixed and implanted penetrating at an angle between horizontal and surface normal, in the thickness of the myocardial layer (according to ultrasound data in time-shifted mode), to maximize the volume to be treated by the distributors and to allow them to be fixed as close as possible to the epicardium
c. The length of the light distributors (5 cm) is larger than their maximum length in the myocardium to distribute the light over the whole myocardial thickness.
3) A semi-rigid and transparent silicone-type or biodegradable mask is placed and fixed over the epicardial surface of the heart to be treated through 4 points (single strands of 5.0 wire). The mask can be used as both a guide/template for piercing the fixation (pre-drilled at the correct implantation angle and its holes follow a geometric pattern and predefined spacing that allows for the propagation of light in the tissue depending on the wavelength of light used). The mask also serves to hold the puncture fixation catheter into which the light distributor is inserted.
4) Using, for exampleThe catheter is used for fixing the myocardial wall through mask puncture, < + >>The characteristics of the catheter are:
a. less than 20 gauge (to minimize bleeding and tissue damage),
b. the hollow part of the hollow part is provided with a hollow,
c. transparent at the wavelength of use and,
d. a closed end cap, a sealing cover and a sealing cover,
e. visual indicia on the catheter indicates the length of catheter placement.
5) Connected to an optical splitter device and then subjected to an optical calibration step
6) Introducing a light distributor into each conduit (similar toInterstitial processes used in photodynamic therapy). The dispenser is attached to the catheter by means of a "luer lock". All light distributors are attached to the mask and/or the patient skin.
7) The temporal evolution of the light power emitted by the light distributor is determined such that the treated cells receive the best spatial irradiance ("fluence rate") in the best time. The determination is made based on the number and location of the light distributors determined by the user. For example, it consists in deriving the temporal evolution of the optical power emitted by the optical splitter from a preset weighting matrix. These matrices are generated based on monte carlo-type simulations of light propagation in the tissue of interest and a cost reduction algorithm that takes into account the specificity (optical and biological) of each wavelength for optimizing the processing time.
The optical delivery is performed in such a way that the temporal evolution of the optical power of the light source is performed according to the determination described in the previous step. Which can be adjusted by monitoring methods based on various instruments or biological data as previously described. A simplified diagram is presented in fig. 15, illustrating an example of a portion of an apparatus for providing an optical splitter.
In the case of a single irradiation:
i. surgical reperfusion procedure
Catheter and mask removal
Hemostasis, if necessary at the puncture fixation point
Verification of light distributor calibration
And v, continuing the surgical intervention as usual.
Normal closing procedure as any sternotomy.
In the case of multiple irradiation:
i. surgical reperfusion procedure
The catheter and light distributor are placed in position and attached to the biodegradable mask. The light distributor may be passed through the cannula into the skin, fixed and placed in place for 8 to 10 days in order to remotely repeat the process.
Surgical intervention is continued as usual.
Normal closing procedure as any sternotomy.
Removal of the light distributor is performed with the chest drainage in place by simple manual removal accompanied by ultrasonography at the second hour.
Intra-luminal medical device
This involves percutaneous placement of one or more light distributors into the left ventricle under fluoroscopy by an interventional cardiologist during myocardial revascularization in the acute phase of MI, in a pre-treatment, treatment or post-treatment.
These light distributors are placed at the beginning of the procedure and then add blood supply to the occluded coronary heart vessels.
These optical splitters are implanted according to the following procedure:
1) Access to the radial or femoral artery is achieved by ultrasonic puncture.
2) A radiation focusing (radio) guide sheath (5F-6F) was introduced using the Seldinger method.
3) Under fluoroscopy, the catheter is navigated to the left ventricle using radiation focused diagnostic guidance after crossing the aortic valve. The guide is removed and placed through a diagnostic catheter with or without a self-expanding systolic balloon in the left ventricle, or a light distributor fixed directly to the ischemic left ventricle wall.
4) Light delivery. The determination of the temporal evolution of the optical power emitted by the optical splitter and the optical delivery are performed as described above.
5) Removal of the catheter, light distributor and sheath; the device may be left in place for 8 to 10 days.
6) The conventional procedure of reperfusion of an occluded coronary artery by interventional radiology.
Intravascular medical device
This involves the percutaneous placement of one or more light distributors in an artery during MI, lung or other organ transplantation that suffers from ischemia reperfusion phenomena, during pre-treatment, treatment or post-treatment, under fluoroscopy, during revascularization following ischemia phenomena in interventional radiology, whatever the artery is.
These light distributors are placed at the beginning or end of the process before reperfusion.
These optical splitters, in the case of coronary arteries, are implanted according to the following procedure:
1) Use of I.V. catheterRadial or femoral artery movement)The pulses are close.
2) Radiation focusing sheath (5F-6F) was introduced using the Seldinger method.
3) Under fluoroscopy, navigation is performed using a diagnostic catheter (4 f, jr 4) and a 0.035 "guide (radiation focusing) to the coronary arteries.
4) The guide and placement of the light distributor is removed through the diagnostic catheter.
5) Light delivery. The determination of the temporal evolution of the optical power emitted by the optical splitter and the optical delivery are performed as described above.
6) Removal of the catheter, light distributor and sheath.
7) Coronary reperfusion procedure as usual.
These processes can be transferred to heart transplantation because it is well known that ischemia reperfusion injury is a major problem during organ transplantation, which is a major cause of graft rejection.
By extension, the above procedure can also be applied to other organs that suffer from ischemia reperfusion injury, as is the case, for example, for kidneys, liver, spleen or brain. These processes may be combined with other processes to simultaneously irradiate different parts of the body, such as the thyroid gland, to control possible negative systemic reactions caused by the organ suffering from I/R.
Example 2: continuous time variation of irradiance (or power) emitted by the light source.
Since Δf' defined in the detailed description is greater than zero, the temporal evolution of irradiance (or power) delivered by the light source may be continuous rather than incremental (as shown by the dashed line fitting the histogram in fig. 10 and 11). In this case, the temporal evolution of the irradiance or power delivered by the light distributor is given by equations 5 and 7, respectively.
Example 3: the irradiance (or power) emitted by the light source decreases over time rather than increases.
Different tissue layers of thickness deltaz may be irradiated with an appropriate fluence rate while increasing or decreasing (incrementally and/or continuously) irradiance (or power).
In this case t tot The same, but time evolution of irradiance (or power) is given by the following expression, respectively: e (t) = (F'/k) ·e ΔF’.(ttot-t)/F’.T Or P (t) = (S.F'/k) e ΔF’.(ttot-t)/F’.T ,(0<t<t tot )。
Example 4: different illumination (light delivery) geometries.
Fig. 5 shows the spatial distribution of fluence rates for a particular geometry (i.e. in semi-infinite tissue illuminated with broad, collimated and perpendicular beams at the air-tissue interface). It is well known in the field of photomedicine, in particular in photo-bioregulation or LLLT, to consider different illumination geometries depending on tissue/organ structure and pathway. Fig. 6 illustrates some of the most common illumination geometries.
There are solutions to the diffusion approximation for many of these geometries to determine fluence rates. Thus, for other illumination, organ, and/or light delivery geometries, the general expression of equation 5 can be written as: e (t) =f E (μ a ,μ s ,g,n ext ,n tissue F ', ΔF', S, T, T), where F E Is a function that depends on tissue optical parameters, organ and illumination geometry, fluence rate and its FWHM and illumination time that produces local maxima of the PBM effect. Many different methods are known for determining F E As described in example 6 below.
Similarly, the general expression of equation 7 for other illumination, organ, and/or light delivery geometries can be written as: p (t) =f P (μ a ,μ s ,g,n ext ,n tissue F ', ΔF', S, T, T), where F P Is a function that depends on tissue optical parameters, organ and illumination geometry, fluence rate and its FWHM and illumination time that produces local maxima of the PBM effect. Many different methods are known for determining F P As described in example 6 below.
A combination of the light delivery geometries presented in fig. 16 may also be used. Obviously, it is certainly also conceivable to use light sources in a direct or quasi-contact manner, such as ex-situ or in-situ LEDs or VCSELs.
Finally, it is certainly also possible to envisage heterogeneous organization, in particular hierarchical organization.
Example 5: different tissue optical properties.
The above form is specific to mu due to the different optical properties of different types of tissue a 、μ s 、g、n ext 、n tissue Is effective, especially if these optical properties change for a given tissue during irradiation.
Example 6: the fluence rate is estimated using other methods than diffusion-based approximation.
Different approaches have been established to model the propagation of light in biological tissues [ marteli, 2009]. Thus, these methods may be used to determine the temporal evolution of the light source to produce the optimal PBM effect instead of or in combination with the form of diffusion approximation based on the light transmission equation described above. These methods are developed mainly in the field of photo-medicine, and are used to master the dosimetry of light in tissues, and are divided into two categories:
1) The analysis method comprises the following steps: in addition to the well-known diffusion approximation of light transmission theory (which is used to establish the forms set forth in the detailed description of the invention above), other analytical methods are well established in the art, including but not limited to: the Kubelka-Munk theory, delta-Eddington radiation transmission equation.
2) A computer-based method of: many computer-based methods have been proposed for decades to simulate the propagation of light in biological tissues. These methods include, but are not limited to: monte carlo simulation, finite element simulation.
Example 7: different tissue responses to PBM are considered depending on cell type, wavelength (spectral design) and metabolic activity.
F' (3 mW/cm) 2 )、ΔF’(1.6mW/cm 2 ) And T (180 s) from our samples (human cardiomyocytes: HCM), environment (medium, temperature, pO 2 Etc.) and spectral design (only at 689nmNext, one irradiation) was performed. However, in particular, changing one or a combination of these conditions may result in different values of F ', Δf' and T. This is especially the case if the time diagram of the application of the light changes.
Thus, the concepts presented above can be generalized to different conditions and cell types.
Example 8: in radiometric conditions (irradiance/fluence) corresponding to a plurality of "hot spots" in fig. 4a and 4b
Rate, duration/dose) of irradiation of tissue.
It should be emphasized that the number of the components,FIGS. 4a and 4bSeveral "hot spots" are presented. Two "hot spots", i.e. the one mentioned above, corresponding to 3mW/cm 2 Irradiance and irradiation time of 180s (hot spot 1), and irradiance and irradiation time of the second are 15mW/cm, respectively 2 And 40s (hot spot 2).
This is important, in particular, to minimize the total treatment time.
In practice, since a "high" irradiance cannot be applied without damaging the tissue, only tissue located "close" to the illuminated surface can be irradiated with 15mW/cm 2 Is treated with a "high" irradiance. Otherwise, cells close to the light source may experience thermal damage when cells at a distance receive a relatively high fluence rate.
It is widely accepted in the scientific community in this field that if the cross-sectional area is wide (diameter greater than μ eff -1 ) Is applied with hundreds of mW/cm during a period of time exceeding a few seconds 2 The thermal effect will begin to be noticeable if the irradiance of red (or NIR) light.
FIGS. 17 and 18 below illustrate that if irradiance must be less than 100mW/cm 2 (other conditions that are the same as those considered in fig. 10 and 11), how the presence of "hot spot 2" is exploited to minimize processing time.
In this case, the treatment algorithm is as follows:
so long as E<100mW/cm 2 The temporal evolution of the irradiance (or power) is then calculated by equation 5 #Or 7) wherein: f' =15 mW/cm 2 ;ΔF’=4mW/cm 2 And t=40s. Otherwise, the value of F' must be used = 3mW/cm 2 ;ΔF’=1.6mW/cm 2 And t=180 s.
This example can be extended by using a combination of wavelengths within their own hotspots.
Example 9: using passive attenuators to generate irradiance (or work) using a Continuous Wave (CW) light source according to equations 5 and 7
Rate) of the time evolution of the rate.
There are many commercially available light sources for treating tissue by PBM. Needless to say, none of them produces irradiance (or power) according to equation 5 (or 7). However, since many of these commercial light sources emit CW light and generate more than 0.62mW/cm 2 (under our specific conditions, 3mW/cm 2 Divided by k=4.87), they can be combined with attenuators so that they change their transmission over time in such a way that the irradiance corresponds to the value given in equation 5.
More precisely, if E' is the irradiance generated at 689nm by such a source without an attenuator, the attenuator transmits (T r ) The time evolution of (2) will be given by: t (T) r (t) =e (t)/E', where E (t) will be given by equation 5.
In summary, the specific design of the device according to the invention must combine a CW light source with one or more attenuators to finally obtain irradiance corresponding to that given in equation 5.
The generalizations mentioned in examples 1 to 8 above also apply to this example.
Example 10: high frequency adjustment of light superimposed on the temporal evolution of irradiance or power given in example 4 is used.
Because biological objects have dynamic optical absorption and response to light, due in part to their dynamic change in redox state, the wavelength or multiplexing wavelength for PBM can be synchronized/tuned at higher frequencies than the time variation defined in equation 5, taking into account the dynamics of oxidative metabolic redox states.
Example 11: according to equations 5 and 7, irradiance (or work) is modified by a pulsed light source using pulse duration variations
Rate).
As already mentioned in example 10, the light may be adjusted at a higher frequency than the frequency for irradiance (or power or fluence rate) variation according to equations 5 and 7. Since the average power P (t) is the time average of the following pulsed optical power P (t):
P(t)=∫p(t)dt
the time evolution of P (t) can be varied for a given frequency and peak power by adjusting the duty cycle of P (t).
Example 12: causing bystanders or remote effects.
As observed by the inventors under total blood volume irradiation performed in the central venous line paO 2 And other arterial gases (e.g., chloride ions) occur only in arterial blood, either transiently or intermediately but with significant regulation. In fact, these modulations were not observed in the central venous blood (see figures 25b and c). Since PBM is known to cause bystander or remote effects under certain conditions, it is of great interest to irradiate different parts of a biological object (including circulating objects such as blood) simultaneously or sequentially.
Example 13: circulating biological subjects entering the blood or lymphatic vessels are treated by PBM.
1) Temporal variations in light power or irradiance may be performed to illuminate a circulating biological object passing near the light distributor over a range of fluence rates. The expression of irradiance and power given in example 4 can be adjusted to account for the different velocities of biological objects of blood or lymphatic vessels for which the PBM is directed.
2) The power of the light is synchronized with hemodynamic variables, such as flow changes due to heartbeat and vasomotor, to optimally illuminate the target biological object within the blood stream.
For example, in order to bypass the negative consequences of SARS-CoV-2, and more generally in the case of ARDS, to optimize the immune response, the hemoglobin oxygen affinity, the thrombotic process and promote tissue regeneration, especially by using the bystander effect of PBM by inserting one or more light distributors in the blood vessel (e.g. pulmonary artery), has shown impressive positive effects, as demonstrated by the inventors.
In particular, an example of a clinical procedure ("Seldinger method") for locating light distributors in the right and left pulmonary arteries is described below:
1. venous access was performed by right jugular vein puncture under ultrasound imaging using an i.v catheter (Surflo, terumo).
2. A 7Fr sheath (radiation focus, terumo) was introduced using the Seldinger method.
3. Under fluoroscopic guidance, a 4fr JR4 guide catheter (Cordis) was used, using a non-hydrophilic 0.035 inch guidewire (Terumo) to engage the right pulmonary artery ostium.
4. The 0.035 inch guidewire was removed and a hemostatic valve Y-connector was connected to the 4Fr JR4 guide catheter.
5. An optical distributor was placed between the upper right lobe and the lower right lobe pulmonary artery inlet through a 4fr JR4 guide catheter.
6. The 4Fr JR4 guide catheter was completely removed from the 7Fr sheath.
7. The 4fr JR4 guide catheter was flushed with saline through the hemostatic valve Y-connector.
8. Using the same procedure as described in figures 3, 4, 5 and 6, a second 4fr JR4 guide catheter was used to place a second light distributor between the inlets of the upper left and lower left pneumoconiosis arteries.
9. The 2 light dispensers (cannulated in the 4fr JR4 guide catheter) were attached to the skin using an adhesive system (Grip Lock, vygon).
As shown in fig. 20, the protocol may be adapted to perform PBM irradiation, wherein one optical splitter is placed in the atrium and the inferior and superior vena cava. The light distributor may be left for days or weeks to repeat the treatment periodically.
Example 14): combinations of different illumination schemes.
The PBM effect is caused by the absorption of light by different primary photoreceptors, particularly leading to a number of signal and transcription factor changes. PBM light is also known to photolyze NO from nitrosohemoglobin and to affect Nitrate Reductase Activity (NRA) which is involved in certain metalloproteins, which also releases unstable NO in the presence of hypoxia tension and nitrite. Since NO is recognized in mild or deep hypoxemia, different irradiation schemes must be considered to activate different mechanisms. For example, in circulating blood, a first lighting scheme may consist in delivering, at a suitable wavelength, a constant or pulsed irradiance/fluence rate (as high power as possible while avoiding thermal effects, i.e. typically several hundred mw.cm) applied during an optimal time (ranging from a few seconds to a few minutes) -2 ) The aim is for example photodissociation of nitrosylhemoglobin or of thiohemoglobin. This first irradiation scheme must be combined with a second scheme based on the hot spot concept described above.
Example 15: irradiation of biological objects can be performed by specific selection of hot spots, in particular for a duration of time Optimizing the treatment in this respect.FIG. 21 shows the use of the hot dotted line (10.+ -. 9,5 mW.cm) -2 The method comprises the steps of carrying out a first treatment on the surface of the 40 s). The figure depicts the fluence rate of illumination from a cylindrical dispenser to the myocardium at 689nm using a second class of bessel functions. Using this hot spot line, the first 40s period was 2.8mw.cm to a cylindrical dispenser -1 Is equal to 20mW.cm (corresponding to the surface of the distributor) -2 Is the first 3.5mm of fluence rate) that can be treated. Then 100mW.cm was used -1 The second period of 40s of power for treating tissue between 3.5 and 7 mm.
Example 16: irradiation of the biological object may be performed in synchronization with parameters corresponding to the plurality of hotspots.As shown in fig. 22, since the fluence rate decreases with increasing distance from the light distributor, when a high fluence rate (e.g. 15 or 25mW/cm 2 ) In treating tissue proximate to the light distributor, the remote or deep tissue is exposed to a low fluence rate (e.g. 3mW/cm 2 ). This can be used to optimize the treatment time as well as for specific parts of the biological object.
Example 17: using several PBM effective wavelengths exhibiting different penetration depths in tissue based on synchronization or sequence Treatment regimen. As shown in fig. 23, as fluence rate decreases with increasing distance from the light distributor, distant or deep tissue is treated with a penetration wavelength corresponding to the "hot spot" presented in fig. 4a and b for a fluence rate and duration, whereas tissue near the surface is treated with less penetration wavelength corresponding to the same "hot spot". This can be used to optimize the treatment time as well as for specific parts of the biological object.
Example 18: is a medical device for treating bone marrow and inducing cell lines designed for percutaneous introduction of bone marrow, strands Bone, tibia, iliac crest or other medullary area. Which includes one or more optical fibers. These fibers are placed in a catheter sheath that can be attached to the skin. The distal end of the optical fiber is sealingly connected to the catheter by an SMA connector connected to the source. The proximal end can be adjusted (between 2 and 8 cm) by retracting the catheter sheath, allowing for deployment of an optical fiber reinforced with a rigid material introduced into the spinal cord.
Example 19: increasing and homogenizing endogenous production of PpIX to improve photodynamic detection (PDD) and PDT performance. Embodiments of this surprising effect include:
1) Helmets with integrated light emitting diodes are used, which induce PBM irradiation through the skull over specific areas of the brain between 6 and 72 hours prior to PDD or PDT process, to treat brain cancers (including glioblastoma).
2)Increasing and homogenizing endogenous production of PpIX in plants and larvae. One example of such a method is in the agricultural field to increase the efficacy of phototoxic effects induced in grasses/larvae. It can be adapted to a variety of agricultural engines.
Example 20: triggering or spatial resynchronization of metabolic activity of biological objects. Spatial synchronization of metabolic activity is necessary to maintain local or systemic homeostasis and to allow blood flow in arterial or venous capillaries. Notably, the blood vesselsSynchronous local contraction from one location to another may cause vasomotor. These contractions can be seen as spatial wavefronts that move all the way along the blood vessel. For example, disruption of these synchronous contractions by impaired myogenic conduction may be responsible for many vascular lesions. Since it has been shown that different parts of a biological object can be targeted sequentially or consecutively by selecting specific hot spots, and since PBM can modulate or trigger specific metabolic activities, in particular within a myogenic frequency range, irradiation of damaged blood vessels, for example at specific distances (equal to the length defined by the spatial period of the contraction wave), can maintain the contraction from one location to another synchronous or trigger contraction from one location to another to restore blood flow in case of myogenic dysregulation.
Reference to the literature
C.,Boedtkjer,D.&Matchkov,V.,2011.Vasomotion–what is currently thoughtActa Physiologica,202(3),pp.253–269./>
Acharya,U.R.et al.,2017.Application of higher-order spectra for the characterization of Coronary artery disease using electrocardiogram signals.Biomedical Signal Processing and Control,31,pp.31–43.Available at:http://dx.doi.org/10.1016/j.bspc.2016.07.003
B.Alberts,A.Johnson,J.Lewis,M.Raff,K.Roberts,and P.Walter,Molecular Biology of the Cell,4th ed.Garland Science,2002.
R.C.et al.,2018.Cardiac Hemodynamic Monitoring in the Subcutaneous Space:A pre-clinical proof-of-concept.MeMeA 2018-2018 IEEE International Symposium on Medical Measurements and Applications,Proceedings.
F.Antunes,A.Boveris,and E.Cadenas,“On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide,”Proc.Natl.Acad.Sci.U.S.A.,vol.101,no.48,pp.16774–16779,Nov.2004.
Bailey,S.M.,Udoh,U.S.&Young,M.E.,2014.Circadian regulation of metabolism.Journal of Endocrinology,222(2).DOI:https://doi.org/10.1530/JOE-14-0200.
K.A.Ball,P.R.Castello,and R.O.Poyton,“Low intensity light stimulates nitrite-dependent nitric oxide synthesis but not oxygen consumption by cytochrome c oxidase:Implications for phototherapy,”J.Photochem.Photobiol.B,vol.102,no.3,pp.182–191,Mar.2011.
S.Banerjee and D.K.Bhatt,“Histochemical studies on the distribution of certain dehydrogenases in squamous cell carcinoma of cheek,”Indian J.Cancer,vol.26,no.1,pp.21–30,Mar.1989.
M.A.Beilke,C.Collins-Lech,and P.G.Sohnle,“Effects of dimethyl sulfoxide on the oxidative function of human neutrophils,”J.Lab.Clin.Med.,vol.110,no.1,pp.91–96,Jul.1987.
I.Bentov and M.J.Reed,“The effect of aging on the cutaneous microvasculature,”Microvasc.Res.,vol.100,pp.25–31,2015
Bhattacharyya,A.et al.,2018.A novel approach for automated detection of focal EEG signals using empirical wavelet transform.Neural Computing and Applications,29(8),pp.47–57.
Bhoi,A.K.,Sherpa,K.S.&Khandelwal,B.,2017.Arrhythmia and ischemia classification and clustering using QRS-ST-T(QT)analysis of electrocardiogram.Cluster Computing,21(1),pp.1033–1044.
Bigarella,C.L.,Liang,R.&Ghaffari,S.,2014.Stem cells and the impact of ROS signaling.Development(Cambridge),141(22),pp.4206–4218.
T.S.Blacker and M.R.Duchen,“Investigating mitochondrial redox state using NADH and NADPH autofluorescence,”Free Radic.Biol.Med.,vol.100,no.Supplement C,pp.53–65,Nov.2016.
Blackstone,E.,Morrison,M.&Roth,M.B.,2005.H2S induces a suspended animation-like state in mice.Science,308(5721),p.518.
Bleys,J.,Navas-Acien,A.&Guallar,E.,2008.Serum selenium levels and all-cause,cancer,and cardiovascular mortality among US adults.Archives of Internal Medicine,168(4),pp.404–410.
Brandes,R.P.,Weissmann,N.&K.,2014.Nox family NADPH oxidases in mechano-transduction:Mechanisms and consequences.Antioxidants and Redox Signaling,20(6),pp.887–898.
M.Butawan,R.L.Benjamin,and R.J.Bloomer,“Methylsulfonylmethane:Applications and Safety of a Novel Dietary Supplement,”Nutrients,vol.9,no.3,Mar.2017.
Bos,E.M.et al.,2009.Hydrogen sulfide-induced hypometabolism prevents renal ischemia/reperfusion injury.Journal of the American Society of Nephrology,20(9),pp.1901–1905.
M.,Wilcox,C.S.&Arendshorst,W.J.,2015.Renal autoregulation in health and disease.Physiological Reviews,95(2),pp.405–511.
B.Chance,B.Schoener,R.Oshino,F.Itshak,and Y.Nakase,“Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples.NADH and flavoprotein fluorescence signals,”J.Biol.Chem.,vol.254,no.11,pp.4764–4771,Jun.1979.
B.Chance,“Metabolic Heterogeneities in Rapidly Metabolizing Tissues,”J.Appl.Cardiol.,vol.4,no.4,pp.207–221,1989.
Chouchani E.T.,1,2 Victoria R.Pell,3 Andrew M.James,4 Lorraine M.Work,5 Kourosh Saeb-Parsy,6 Christian Frezza,7 Thomas Krieg,3 and Michael P.Murphy4,“A Unifying Mechanism for Mitochondrial Superoxide Production during Ischemia-Reperfusion Injury”,Cell Metabolism 23,February 9,2016.
Chouchani,E.T.et al.,2014.Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS.Nature,515(7527),pp.431–435.
Chung H,Dai T,Sharma S,Huang Y,Carroll J,Hamblin M.The Nuts and Bolts of Low-level Laser(Light)Therapy.Ann Biomed Eng.2012;40(2):516-533.doi:10.1007/s10439-011-0454-7.
C.E.Cooper and G.C.Brown,“The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide,nitric oxide,hydrogen cyanide and hydrogen sulfide:chemical mechanism and physiological significance,”J.Bioenerg.Biomembr.,vol.40,no.5,pp.533–539,Oct.2008.
Dasgupta,A.,2014.Cardiac Markers.Clinical Chemistry,Immunology and Laboratory Quality Control,pp.127–144.https://doi.org/10.1016/B978-0-12-407821-5.00008-5.
Devasagayam TP,Tilak JC,Boloor KK,Sane KS,Ghaskadbi SS,Lele RD,"Free radicals and antioxidants in human health:current status and future prospects".The Journal of the Association of Physicians of India.52:794–804,2004.
Di Gialleonardo V.,David M.Wilson,and Kayvan R.Keshari,“The Potential of Metabolic Imaging”,Semin.Nucl.Med.,46(1):28–39,2016.
Donald JA.Gasotransmitter Family.In:Handbook of Hormones.Elsevier;2016:601.doi:doi.org/10.1016/B978-0-12-801028-0.00103-3.
Duan,J.et al..Metabolic remodeling induced by mitokines in heart failure.Aging(Albany NY).2019 Sep 15;11(17):7307–7327.
Ferraresi C.,M.R.Hamblin,and N.A.Parizotto,“Low-level laser(light)therapy(LLLT)on muscle tissue:performance,fatigue and repair benefited by the power of light,”Photonics Lasers Med.,vol.1,no.4,pp.267–286,Nov.2012.
Ferrari R.,MD,PhD;Cristina Balla,MD;Michele Malagù,MD;GabrieleGuardigli,MD;Giampaolo Morciano,MD,PhD;Matteo Bertini,MD;Simone Biscaglia,MD;Gianluca Campo,MD,“Reperfusion Damage―A Story of Success,Failure,and Hope”,Circ J,81:131–141,2017.
Fu M,Zhang W,Wu L,Yang G,Li H,Wang R.,“Hydrogen sulfide(H2S)metabolism in mitochondria and its regulatory role in energy production”,Proc Natl Acad Sci U S A.,109(8):2943-8,2012.
Fuss T.L.,B.A.and Leo L.Cheng,“Metabolic Imaging in Humans”,Top Magn Reson Imaging,25(5):223–235,2016.
R.A.Gatenby and R.J.Gillies,“Why do cancers have high aerobic glycolysis?,”Nat.Rev.Cancer,vol.4,no.11,pp.891–899,Nov.2004.
Grimolizzi,F.&Arranz,L.,2018.Multiple faces of succinate beyond metabolism in blood.Haematologica,103(10),pp.1586–1592.
Griendling,K.K.et al.,2016.Measurement of Reactive Oxygen Species,Reactive Nitrogen Species,and Redox-Dependent Signaling in the Cardiovascular System:A Scientific Statement from the American Heart Association,Circulation journal,119,5,39-65.
Hamblin M.,M.Victor Pires de Sousa and T.Agrawal,“Handbook of Low-Level Laser Therapy”,Pan Stanford Publishing Pte.Ltd.,Singapore,2017.
Hamblin M.,C.Ferraresi,Y.-Y.Huang,L.F.de Freitas,and J.Carroll,“Low-level light therapy:photobiomodulation”,Editor:SPIE Press,Bellingham,Washington,USA,2018.
Hayyan M,Hashim MA,AlNashef IM(March 2016)."Superoxide Ion:Generation and Chemical Implications".Chemical Reviews.116(5):3029–85.
Hellmann,M.,Roustit,M.&Cracowski,J.L.,2015.Skin microvascular endothelial function as a biomarker in cardiovascular diseases?Pharmacological Reports,67(4),pp.803–810.
Huang,Ying-Ying,Carroll JD,H.M.,2009.Biphasic dose response.Dose response,pp.358–383.http://dx.doi.org/10.2203/dose-response.09-027.Hamblin
Hwang,J.et al.,2003.Pulsatile Versus Oscillatory Shear Stress Regulates NADPH Oxidase Subunit Expression:Implication for Native LDL Oxidation.Circulation Research,93(12),pp.1225–1232.
Iwata,A.et al.,2015.Selenide Targets to Reperfusing Tissue and Protects It From Injury*.Read Online:Critical Care Medicine|Society of Critical Care Medicine,43(7).
Jacques S.,“How tissue optics affect dosimetry of photodynamic therapy”,Journal of Biomedical Optics 15(5),051608,2010.
Jekell,A.et al.,2004.Elevated circulating levels of thioredoxin and stress in chronic heart failure.The european Journal of Heart failure,6,pp.883–890.
Jackson,W.F.,2016.Arteriolar oxygen reactivity:where is the sensor and what is the mechanism of actionJournal of Physiology,594(18),pp.5055–5077.
S.Kalinina et al.,“Correlative NAD(P)H-FLIM and oxygen sensing-PLIM for metabolic mapping,”J.Biophotonics,vol.9,no.8,pp.800–811,Aug.2016.Kalogeris T.,Christopher P.Baines1,2,3,Maike Krenz1,2,and Ronald J.Korthuis Ischemia/Reperfusion,Compr Physiol.;7(1):113–170,2017.
T.I.Karu,L.V.Pyatibrat,and N.I.Afanasyeva,“Cellular effects of low power laser therapy can be mediated by nitric oxide,”Lasers Surg.Med.,vol.36,no.4,pp.307–314,Apr.2005.
Kennedy R.T.,et al.,《Metabolic oscillations in-cells》,Diabetes,51(S1),2002.
Y.H.Kim,D.H.Kim,H.Lim,D.-Y.Baek,H.-K.Shin,and J.-K.Kim,“The anti-inflammatory effects of methylsulfonylmethane on lipopolysaccharide-induced inflammatory responses in murine macrophages,”Biol.Pharm.Bull.,vol.32,no.4,pp.651–656,Apr.2009.
Kindo,M.et al.,2016.Left Ventricular Transmural Gradient in Mitochondrial Respiration Is Associated with Increased Sub-Endocardium Nitric Oxide and Reactive Oxygen Species Productions.Frontiers in physiology,7(August),pp.1–8.
Kindo,M.et al.,2012.Pressure overload-induced mild cardiac hypertrophy reduces left ventricular transmural differences in mitochondrial respiratory chain activity and increases oxidative stress.Frontier in physiology,3(August),pp.1–14.
Kondo K,Bhushan S,King AL,Prabhu SD,Hamid T,Koenig S,et al.“H 2 S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase”,Circulation,127:1116–1127,2013.
C.et al.,2012.Hydrogen sulfide:Potent regulator of vascular tone and stimulator of angiogenesis.International Journal of Biomedical Science,8(2),pp.81–86.
Kuganesan,M.et al.,2019.Selenium and hydrogen selenide:essential micronutrient and the fourth gasotransmitterIntensive Care Medicine Experimental,7(1).http://dx.doi.org/10.1186/s40635-019-0281-y.
Kumar,M.,Pachori,R.B.&Acharya,U.R.,2017.Characterization of coronary artery disease using flexible analytic wavelet transform applied on ECG signals.Biomedical Signal Processing and Control,31,pp.301–308.
Kvandal,P.et al.,2006.Low-frequency oscillations of the laser Doppler perfusion signal in human skin.Microvascular Research,72(3),pp.120–127.
N.Lane,“Cell biology:power games,”Nature,vol.443,no.7114,pp.901–903,Oct.2006.
Latham,F.,1951.THE OXYGEN PARADOX EXPERIMENTS ON THE EFFECTS OF OXYGEN IN HUMAN ANOXIA.The Lancet,257(6646),pp.77–81
Li,S.&Yang,G.,2015.Hydrogen Sulfide Maintains Mitochondrial DNA Replication via Demethylation of TFAM.Antioxidants and Redox Signaling,23(7),pp.630–642.
Li,Y.S.J.,Haga,J.H.&Chien,S.,2005.Molecular basis of the effects of shear stress on vascular endothelial cells.Journal of Biomechanics,38(10),pp.1949–1971.
Li,Y and Patrick J.Pagano,2017.Microvascular NADPH oxidase in health and disease.Free Radic Biol Med.,109(1),pp.33–47.
Liebert,A.et al.,2017.A Role for Photobiomodulation in the Prevention of Myocardial Ischemic Reperfusion Injury:A Systematic Review and Potential Molecular Mechanisms.Scientific Reports,7(February),pp.1–13.Available at:http://dx.doi.org/10.1038/srep42386.
N.L.Lohr,A.Keszler,P.Pratt,M.Bienengraber,D.C.Warltier,and N.Hogg,“Enhancement of nitric oxide release from nitrosyl hemoglobin and nitrosyl myoglobin by red/near infrared radiation:potential role in cardioprotection,”J.Mol.Cell.Cardiol.,vol.47,no.2,pp.256–263,Aug.2009.
Loutzenhiser,R.,Bidani,A.&Chilton,L.,2002.Renal myogenic response:Kinetic attributes and physiological role.Circulation Research,90(12),pp.1316–1324.
Martelli F.,Del Bianco S.,Ismaelli A.,“Light propagation throughbiological tissue and other diffusive media:theory,solutions,and software”,Bellingham:Society of Photo-Optical Instrumentation Engineers,2009.
IrmaRegina />Voltage-Sensitive Fluorescence of Indocyanine Green in the Heart,Biophysical Journal,Volume 110,Issue 3,2016,Pages 723-732,ISSN 0006-3495.
Moldogazieva,N.T.et al.,2018.ROS and RNS signalling:adaptive redox switches through oxidative/nitrosative protein modifications.Free Radical Research,52(5),pp.507–543.Available at:https://doi.org/10.1080/ 10715762.2018.1457217.
Moss,N.G.,Gentle,T.K.&Arendshorst,W.J.,2016.Modulation of the myogenic mechanism:Concordant effects of NO synthesis inhibition and O-2 dismutation on renal autoregulation in the time and frequency domains.American Journal of Physiology-Renal Physiology,310(9),pp.F832–F845.
Nachiappan,Vasanthi;Muthukumar,Kannan,"Cadmium-induced oxidative stress in Saccharomyces cerevisiae".Indian Journal of Biochemistry and Biophysics.47(6),2010.
Nagpure,B.V.&Bian,J.S.,2016.Interaction of Hydrogen Sulfide with Nitric Oxide in the Cardiovascular System.Oxidative Medicine and Cellular Longevity,2016.
Nakamura,H.,2004.Thioredoxin as a Key Molecule in Redox Signaling.Antioxidants and Redox Signaling,6(1),pp.15–17.
Nowak-Sliwinska P.,J.-P.Ballini,G.Wagnières,and H.van den Bergh,“Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model,”Microvasc.Res.,vol.79,no.1,pp.21–28,Jan.2010.
P.T.Nowicki,S.Flavahan,H.Hassanain,S.Mitra,S.Holland,P.J.Goldschmidt-Clermont,N.A.F.,2001.Redox Signaling of the Arteriolar Myogenic Response.Circulation research,89,pp.114–116.
Olson,K.R.,2012.A practical look at the chemistry and biology of hydrogen sulfide.Antioxidants and Redox Signaling,17(1),pp.32–44.
Papagiannakis A,Niebel B,Wit E,Heinemann M,Autonomous Metabolic Oscillations Robustly Gate the Early and Late Cell Cycle.Molecular Cell,Volume,65,Issue 2,19 January 2017,Pages 285-295,https://doi.org/10.1016/j.molcel.2016.11.018.
Park,H.C.et al.,2017.Effect of LED phototherapy on blood lactate level in Taekwondo contest.Mechanisms of Photobiomodulation Therapy XII,10048(February 2017),p.100480I.
Patidar,S.&Pachori,R.B.,2014.Classification of cardiac sound signals using constrained tunable-Q wavelet transform.Expert Systems with Applications,41(16),pp.7161–7170.Available at:http://dx.doi.org/10.1016/j.eswa.2014.05.052.
Patidar,S.,Pachori,R.B.&Rajendra Acharya,U.,2015.Automated diagnosis of coronary artery disease using tunable-Q wavelet transform applied on heart rate signals.Knowledge-Based Systems,82,pp.1–10.Available at:http://dx.doi.org/10.1016/j.knosys.2015.02.011.
Pettersen,F.J.et al.,2016.Bioimpedance measurements of temporal changes in beating hearts.Biomedical Physics and Engineering Express,2(6).
Petrenko,V.et al.,2020.In pancreatic islets from type 2 diabetes patients,the dampened circadian oscillators lead to reduced insulin and glucagon exocytosis.Proceedings of the National Academy of Sciences of the United States of America,117(5),pp.2484–2495
Piper,H.M.,2000.The calcium paradox revisited:An artefact of great heuristic value.Cardiovascular Research,45(1),pp.123–127
N.Ramanujam,R.Richards-Kortum,S.Thomsen,A.Mahadevan-Jansen,M.Follen,and B.Chance,“Low Temperature Fluorescence Imaging of Freeze-trapped Human Cervical Tissues,”Opt.Express,vol.8,no.6,pp.335–343,Mar.2001.
V.Rapozzi,E.Della Pietra,S.Zorzet,M.Zacchigna,B.Bonavida,and L.E.Xodo,“Nitric oxide-mediated activity in anti-cancer photodynamic therapy,”Nitric Oxide Biol.Chem.,vol.30,pp.26–35,Apr.2013.
Raddatz E,Thomas AC and al.Differential contribution of mitochondria,NADPH oxidases,and glycolysis to region-specific oxidant stress in the anoxic-reoxygenated embryonic heart.Am J Physiol Heart Circ Physiol 300:H820–H835,2011.
K.J.Reeves,M.W.R.Reed,and N.J.Brown,“Is nitric oxide important in photodynamic therapy?,”J.Photochem.Photobiol.B,vol.95,no.3,pp.141–147,Jun.2009.
Reglin,B.&Pries,A.R.,2014.Metabolic control of microvascular networks:Oxygen sensing and beyond.Journal of Vascular Research,51(5),pp.376–392.
De Roever I,Bale G,Cooper RJ,Tachtsidis I.”Functional NIRSMeasurement of Cytochrome-C-Oxidase Demonstrates a More Brain-Specific Marker of Frontal Lobe Activation Compared to the Haemoglobins”,Adv Exp Med Biol.2017;977:141-147,2017.
Sachar M.et al.“Protoporphyrin IX:the Good,the Bad,and the Ugly.”The Journal of pharmacology and experimental therapeutics vol.356,2(2016):267-75.doi:10.1124/jpet.115.228130.
Sedmera,D.,Kucera,P.&Raddatz,E.,2002.Developmental changes in cardiac recovery from anoxia-reoxygenation.American Journal of Physiology-Regulatory Integrative and Comparative Physiology,283(2 52-2),pp.379–388.
Shiogai,Y.,Stefanovska,A.&McClintock,P.V.E.,2010.Nonlinear dynamics of cardiovascular ageing.Physics Reports,488(2–3),pp.51–110.
Sies,H.&Jones,D.P.,Reactive oxygen species(ROS)as pleiotropic physiological signalling agents.Nature Reviews Molecular Cell Biology.2020Available at:http://dx.doi.org/10.1038/s41580-020-0230-3.
M.C.Skala et al.,“In vivo multiphoton microscopy of NADH and FAD redox states,fluorescence lifetimes,and cellular morphology in precancerous epithelia,”Proc.Natl.Acad.Sci.,vol.104,no.49,pp.19494–19499,Dec.2007.
M.Skala and N.Ramanujam,“Multiphoton Redox Ratio Imaging for Metabolic Monitoring in vivo,”Methods Mol.Biol.Clifton NJ,vol.594,pp.155–162,2010.
Smirnova,E.et al.,2013.Assessment of endothelial dysfunction in patients with impaired glucose tolerance during a cold pressor test.Diabetes and Vascular Disease Research,10(6),pp.489–497.
Snijder P.M.,AR Frenay,RAde Boer,APasch,J L Hillebrands,H G D Leuvenink and H van Goor,“Exogenous administration of thiosulfate,a donor of hydrogen sulfide,attenuates angiotensin II-induced hypertensive heart disease in rats”,Br J Pharmacol.2015 Mar;172(6):1494–1504.
Stefanovska,A.,2006.Coupled oscillators:Complex but not complicated cardiovascular and brain interactions.Annual International Conference of the IEEE Engineering in Medicine and Biology-Proceedings,pp.437–440
Szabo,C.et al.,2014.Regulation of mitochondrial bioenergetic function by hydrogen sulfide.Part I.Biochemical and physiological mechanisms.British Journal of Pharmacology,171(8),pp.2099–2122.
Tamura,T.,2019.Current progress of photoplethysmography and SPO2 for health monitoring.Biomedical Engineering Letters,9(1),pp.21–36.Available at:https://doi.org/10.1007/s13534-019-00097-w.
Tamura,T.,2018.Seamless Healthcare Monitoring,https://doi.org/10.1007/978-3-319-69362-0
Thomas DD.Breathing new life into nitric oxide signaling:Abrief overview of the interplay between oxygen and nitric oxide.Redox Biol.2015;5:225-233.doi:10.1016/j.redox.2015.05.002.
Ticcinelli,V.et al.,2017.Coherence and coupling functions reveal microvascular impairment in treated hypertension.Frontiers in Physiology,8(OCT),pp.1–20.
Tretter,L.,Patocs,A.&Chinopoulos,C.,2016.Succinate,an intermediate in metabolism,signal transduction,ROS,hypoxia,and tumorigenesis.Biochimica et Biophysica Acta-Bioenergetics,1857(8),pp.1086–1101.Available at:http://dx.doi.org/10.1016/j.bbabio.2016.03.012.
Tsuruoka,N.et al.,2016.Lactate and glucose measurement in subepidermal tissue using minimally invasive microperfusion needle.Biomedical microdevices,(18:19),pp.2–9.http://dx.doi.org/10.1007/s10544-016-0049-z.
Tuchin V.,“Tissue Optics and Photonics:Light-Tissue Interaction”,J of Biomedical Photonics&Eng 1(2),pp 98–134,2015.
Van Leeuwen,S.R.,Baranoski,G.V.G.&Kimmel,B.W.,2017.Three-wavelength method for the optical differentiation of methemoglobin and sulfhemoglobin in oxygenated blood.Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society,EMBS,pp.4570–4573.
Arnoud H.M.van Vliet,Stefan Bereswill,and Johannes G.Kusters,“Ion Metabolism and Transport”,in:Helicobacter pylori:Physiology and Genetics,Mobley HLT,Mendz GL,Hazell SL,editors,Washington(DC):ASM Press;2001.
Wagnières G.et al.,“ln Vivo Fluorescence Spectroscopy and Imaging for Oncological Applications”,Photochemistry and Photobiology,68(5):603-632,1998.
A.Walsh,R.S.Cook,B.Rexer,C.L.Arteaga,and M.C.Skala,“Optical imaging of metabolism in HER2 overexpressing breast cancer cells,”Biomed.Opt.Express,vol.3,no.1,pp.75–85,Jan.2012.
A.J.Walsh et al.,“Optical metabolic imaging identifies glycolytic levels,subtypes,and early-treatment response in breast cancer,”Cancer Res.,vol.73,no.20,pp.6164–6174,Oct.2013.
G.Walther et al.,“Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction:Cross-sectional study,”Arterioscler.Thromb.Vasc.Biol.,vol.35,no.4,pp.1022–1029,2015.
Wilson B.,Patterson M.,“The physics of photodynamic therapy”,Phys.Med.Biol.,(31)4,pp 327-360,1986.
Wood K,Cortese-Krott M and al.Circulating Blood Endothelial Nitric Oxide Synthase Contributes to the Regulation of Systemic Blood Pressure and Nitrite Homeostasis.Arterioscler Thromb Vasc Biol.2013;33:1861-1871.
Wu,M.,Neilson,A.,Swift,A.L.,Moran,R.,Tamagnine,J.,Parslow,D.,Armistead S.,Lemire,K.,Orrell,J.,Teich,J.,Chomicz,S.,Ferrick,D.A.,Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.Am J Physiol Cell Physiol.292,C125–C136,2007.
Wu,D.,Hu,Q.&Zhu,D.,2018.An update on hydrogen sulfide and nitric oxide interactions in the cardiovascular system.Oxidative Medicine and Cellular Longevity,2018.
Yang,G.,2015.H2S epigenetic regulation of vascular cell functions.Cardiovascular Regenerative Medicine,pp.2–5.
Yu XH,Cui LB,Wu K,et al.Hydrogen sulfide as a potent cardiovascular protective agent.Clin Chim Acta.2014;437:78-87.doi:10.1016/j.cca.2014.07.012.
Zhong,X.et al.,2018.Circadian Clock Regulation of Hepatic Lipid Metabolism by Modulation of m6AmRNA Methylation.Cell Reports,25(7),p.1816–1828.e4.
Zhou,G.et al.,2016.Optimal ROS Signaling Is Critical for Nuclear Reprogramming.Cell Reports,15(5),pp.919–925.Available at:http://dx.doi.org/10.1016/j.celrep.2016.03.084.
Claims (53)
1. An apparatus for applying photo-biological modulation (PBM) to a biological object, the apparatus comprising a light source delivering light at an appropriate temporal evolution of its optical power, the apparatus further comprising a processing and/or light control unit determining the appropriate temporal evolution of the optical power based on light delivery geometry on/in the biological object and biological object optical coefficients, characterized in that the processing and/or light control unit is further adapted to: continuously in each portion of the volume of the biological object, causing a PBM effect by generating one or more specific fluence rates during one or more specific times; the specific combined fluence rate and the timeThe parameters are selected from the following groups: at 180+Period 3 of 30s+2mW/cm 2 Or at 80+25s period 11+9mW/cm 2 Or at 40+20s period 16+10mW/cm 2 Or at 15+Period of 10s 25+10mW/cm 2 Or at 40+Period 10 of 1s+9,7mW/cm 2 。
2. The device according to claim 1, comprising a PBM monitoring and/or feedback system designed to adjust the optical power or irradiance based on the PBM effect.
3. The device of claim 1 or 2, comprising a glucose sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the blood glucose level measured by the glucose sensor.
4. The device of any one of the preceding claims, comprising a cardiac output sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence on the cardiac output measured by the cardiac output sensor.
5. A device according to any one of the preceding claims, comprising a krebs cycle enzyme kinetic measurement device, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the enzyme activity measured by the krebs cycle enzyme kinetic measurement device.
6. The device of any one of the preceding claims, comprising means for administering one or more exogenous agents to the biological subject.
7. The device according to any of the preceding claims, comprising a monitoring unit for PBM monitoring and/or feedback of PBM effects, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on the PBM effects monitored by the monitoring unit.
8. The device according to any of the preceding claims, comprising a metabolic monitoring unit, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on metabolic activity of the biological subject measured by the metabolic monitoring unit.
9. A device according to any one of the preceding claims, characterized in that the device is adapted to produce a combined use of wavelengths, at least one of which is inactive when used alone.
10. An apparatus that integrates the adjustment of radiometric and/or spectroscopic conditions used in PBMT based on frequency analysis of monitored parameters reflecting metabolic activity, particularly using wavelet theory.
11. The device according to claim 10, comprising a PBM monitoring and/or feedback system designed to adjust the optical power or irradiance based on the PBM effect.
12. The device of claim 10 or 11, comprising a glucose sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence on the blood glucose level measured by the glucose sensor.
13. The device according to any of the preceding claims 10 to 12, comprising a cardiac output sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the cardiac output measured by the cardiac output sensor.
14. The device according to any of the preceding claims 10 to 13, comprising a krebs cycle enzyme kinetic measurement device, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the enzyme activity measured by the krebs cycle enzyme kinetic measurement device.
15. The device according to any of the preceding claims 10 to 14, comprising means for administering one or more exogenous agents to the biological subject.
16. The device according to any of the preceding claims 10 to 15, comprising a monitoring unit for PBM monitoring and/or feedback of PBM effects, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on the PBM effects monitored by the monitoring unit.
17. The device according to any of the preceding claims 10 to 16, comprising a metabolic monitoring unit, the processing unit being adapted to adjust the light power, light delivery and/or irradiance based on metabolic activity of the biological subject measured by the metabolic monitoring unit.
18. An apparatus predicts an optimal time to start application of PBM light based on a measurement of metabolic activity.
19. A device for performing PBM directly in blood contained in a cardiac compartment, pulmonary artery or vena cava.
20. The device of claim 19, comprising a PBM monitoring and/or feedback system designed to adjust the optical power or irradiance based on the PBM effect.
21. The device of claim 19 or 20, comprising a glucose sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence on the blood glucose level measured by the glucose sensor.
22. The device of any of the preceding claims 19 to 21, comprising a cardiac output sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the cardiac output measured by the cardiac output sensor.
23. The device according to any of the preceding claims 19 to 22, comprising a krebs cycle enzyme kinetic measurement device, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the enzyme activity measured by the krebs cycle enzyme kinetic measurement device.
24. The device of any one of the preceding claims 19 to 23, comprising means for administering one or more exogenous agents to the biological subject.
25. The device according to any of the preceding claims 19 to 24, comprising a monitoring unit for PBM monitoring and/or feedback of PBM effects, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on the PBM effects monitored by the monitoring unit.
26. The device according to any of the preceding claims 19 to 25, comprising a metabolic monitoring unit, the processing unit being adapted to adjust the light power, light delivery and/or irradiance based on metabolic activity of the biological subject measured by the metabolic monitoring unit.
27. An apparatus for optimizing PBM dosimetry based on dynamic changes in distance separating an optical dispenser from a target biological fluid.
28. The device of claim 27, comprising a PBM monitoring and/or feedback system designed to adjust the optical power or irradiance based on the PBM effect.
29. The device of claim 27 or 28, comprising a glucose sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence on the blood glucose level measured by the glucose sensor.
30. The device of any of the preceding claims 27 to 29, comprising a cardiac output sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the cardiac output measured by the cardiac output sensor.
31. The device of any one of the preceding claims 27 to 30, comprising a krebs cycle enzyme kinetic measurement device, and wherein the processing and/or light control unit is adapted to adjust light dosage in dependence of the enzyme activity measured by the krebs cycle enzyme kinetic measurement device.
32. The device of any one of the preceding claims 27 to 31, comprising means for administering one or more exogenous agents to the biological subject.
33. The device according to any of the preceding claims 27 to 32, comprising a monitoring unit for PBM monitoring and/or feedback of PBM effects, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on the PBM effects monitored by the monitoring unit.
34. The device according to any of the preceding claims 27 to 33, comprising a metabolic monitoring unit, the processing unit being adapted to adjust the light power, light delivery and/or irradiance based on metabolic activity of the biological subject measured by the metabolic monitoring unit.
35. A device that exhibits a variable longitudinal light emissivity profile to deliver optimal fluence rates in a moving biological object at different distances from the device light emitting surface.
36. The apparatus of claim 35, comprising a PBM monitoring and/or feedback system designed to adjust the optical power or irradiance based on the PBM effect.
37. The device of claim 35 or 36, comprising a glucose sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence on the blood glucose level measured by the glucose sensor.
38. The device of any of the preceding claims 35 to 37, comprising a cardiac output sensor, and wherein the processing and/or light control unit is adapted to adjust the light dose in dependence of the cardiac output measured by the cardiac output sensor.
39. The device of any one of the preceding claims 35 to 38, comprising a krebs cycle enzyme kinetic measurement device, and wherein the processing and/or light control unit is adapted to adjust light dosage in accordance with the enzyme activity measured by the krebs cycle enzyme kinetic measurement device.
40. The device of any one of the preceding claims 35 to 39, comprising means for administering one or more exogenous agents to the biological subject.
41. The device according to any of the preceding claims 35 to 40, comprising a monitoring unit for PBM monitoring and/or feedback of PBM effects, the processing unit being adapted to adjust the optical power, the light delivery and/or the irradiance based on the PBM effects monitored by the monitoring unit.
42. The device according to any of the preceding claims 35 to 41, comprising a metabolic monitoring unit, the processing unit being adapted to adjust the light power, light delivery and/or irradiance based on metabolic activity of the biological subject measured by the metabolic monitoring unit.
43. A method for applying photo bio-modulation (PBM) to a biological object, wherein light is delivered in a suitable temporal evolution of optical power,determining the power based on the light delivery geometry on/in the biological object and the biological object optical coefficient, characterized in that the PBM effect is further induced by generating one or more specific fluence rates during one or more specific times in each part of the volume of the biological object in succession, the specific combined fluence rate and the time being selected from the following parameter group: at 180 +Period 3 of 30s+2mW/cm 2 Or at 80+25s period 11+9mW/cm 2 Or at 40+20s period 16+10mW/cm 2 Or at 15+Period of 10s 25+10mW/cm 2 Or at 40+Period 10 of 1s+9,7mW/cm 2 。
44. The method of claim 43, comprising the additional step of including the act of at least one exogenous stimulus.
45. The method of claim 44, wherein the exogenous stimulus is an agent.
46. The method of claim 44, wherein the exogenous stimulus is a temperature change.
47. The method of any one of claims 43 to 46, comprising the act of at least two exogenous stimuli, one of the at least two exogenous stimuli being an exogenous agent.
48. The method of any one of claims 43 to 47, wherein the optical power, optical delivery and/or irradiance are used to adjust the amplitude, phase and/or frequency of fluctuations of one or more parameters reflecting metabolic activity of the biological subject.
49. Use of the foregoing device or method as defined in any of the preceding claims for the treatment of Myocardial Infarction (MI) including acute myocardial infarction.
50. Use of a device or method as defined in any one of the preceding claims 1 to 48 for treating a biological subject suffering from ischemia and/or hypoxia/anoxia.
51. Use of a device or method as defined in any one of claims 1 to 48 for the treatment of Acute Respiratory Distress Syndrome (ARDS).
52. Use of a device or method as defined in any one of the preceding claims 1 to 48 for the treatment of metabolic activity disorders.
53. Use of a device or method as defined in any one of the preceding claims 1 to 48 for the treatment of disorders of insulin secretion.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20199710.3 | 2020-10-01 | ||
EPPCT/EP2021/059842 | 2021-04-15 | ||
EP2021059842 | 2021-04-15 | ||
PCT/EP2021/077205 WO2022069755A1 (en) | 2020-10-01 | 2021-10-01 | Device and method for applying photobiomodulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116710177A true CN116710177A (en) | 2023-09-05 |
Family
ID=87836118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180080898.6A Pending CN116710177A (en) | 2020-10-01 | 2021-10-01 | Apparatus and method for applying photo-biological conditioning |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116710177A (en) |
-
2021
- 2021-10-01 CN CN202180080898.6A patent/CN116710177A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Serrage et al. | Under the spotlight: mechanisms of photobiomodulation concentrating on blue and green light | |
US20050234315A1 (en) | Diagnosis of body metabolic emergency state | |
Liebert et al. | A role for photobiomodulation in the prevention of myocardial ischemic reperfusion injury: a systematic review and potential molecular mechanisms | |
Stagnaro et al. | The role of modified mediterranean diet and quantum therapy in oncological primary prevention | |
Rother et al. | Microcirculation evaluated by intraoperative fluorescence angiography after tibial bypass surgery | |
JPWO2008066206A1 (en) | Abnormal electrical conduction blocking device using photodynamic therapy (PDT) | |
d’Avila et al. | Exercise Reverses Peripheral Insulin Resistance in Trained L-NAME–Hypertensive Rats | |
Svalestad et al. | Effect of hyperbaric oxygen treatment on oxygen tension and vascular capacity in irradiated skin and mucosa | |
De Marchi et al. | Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia | |
Mayevsky et al. | Shedding light on mitochondrial function by real time monitoring of NADH fluorescence: II: human studies | |
Skåre et al. | Cerebral perfusion and metabolism with mean arterial pressure 90 vs. 60 mmHg in a porcine post cardiac arrest model with and without targeted temperature management | |
Bertini et al. | Transepidermal water loss and cerebral hemodynamics in preterm infants: conventional versus LED phototherapy | |
Amran et al. | Physiology and Pathology of the Cardiovascular System | |
US20230364442A1 (en) | Device and method for applying photobiomodulation | |
CN116710177A (en) | Apparatus and method for applying photo-biological conditioning | |
EP3978071A1 (en) | Device for applying photobiomodulation | |
AU2021354021A9 (en) | Device and method for applying photobiomodulation | |
Nizinski et al. | Non‐invasive in vivo human model of post‐ischaemic skin preconditioning by measurement of flow‐mediated 460‐nm autofluorescence | |
Mayevsky et al. | Real-time optical monitoring of tissue vitality in vivo | |
Kondo et al. | Photodynamic therapy using a second generation photosensitizer, Talaporfin | |
Mujumdar et al. | Wearable Sensor for Multi-wavelength Near-Infrared Spectroscopy of Skin Hemodynamics Along with Underlying Muscle Electromyography | |
Munteanu et al. | Cellular and Molecular Homeostatic Micro-environmental im-balances in Osteo-arthritis and Rheumatoid Arthritis | |
Życiński et al. | Original article Laser biostimulation in end-stage multivessel coronary artery disease–a preliminary observational study | |
RU2609059C2 (en) | Method of estimating adaptive-compensatory reactions in healthy individuals to remote pre-conditioning | |
Amran et al. | Perspective chapter: Physiology and pathology of the cardiovascular system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40090313 Country of ref document: HK |